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Introduction and Aim 




Chronic heart failure (CHF) is the leading cause of hospitalization in people older than 
age 65 [1].  In developing countries, 2-3 % of the population suffers from heart failure, but in 
those 70-80 years old, it occurs in 20-30 %. CHF is associated with significant morbidity and 
mortality attributable largely to adverse structural changes to the myocardium with related 
cardiac dysfunction (pump failure), arrhythmias and premature sudden death, and other 
associated complications such as renal disease. 
 
Cardiac remodeling and fibrogenesis  
Cardiac remodeling involves changes in size, shape, structure and physiology of the heart 
in response to elevated hemodynamic load and/or cardiac injury in association with 
neurohormonal activation [2]. Remodeling may be described physiologically or pathologically 
[3]. Physiological remodeling has been observed in athletes and has been termed “athlete’s 
heart,” whereas pathological remodeling may occur with pressure overload (e.g. aortic 
stenosis, hypertension), volume overload (e.g. valvular stenosis or regurgitation), or following 
cardiac injury (e.g. myocardial infarction, myocarditis or idiopathic dilated cardiomyopathy). 
In the latter, capillary network density is less and therefore not capable of supplying the 
greater demand of the hypertrophied myocardium. [4-6]. In each of these settings, remodeling 
may transition from an apparently compensatory process to a maladaptive one [7]. The 
transition is specifically associated with changes to both the cellular and extracellular matrix 
(ECM) such as myocyte hypertrophy, apoptosis or necrosis, as well as fibroblast proliferation, 
myofibroblast activation and development of fibrosis. All these changes are influenced by 
various factors including increased hemodynamic load, neurohumoral activation via 
endothelin and cytokines signaling, oxidative stress, matrix metalloproteinases (MMPs), and 
inflammatory responses involving recruitment of peripheral monocytes and macrophages 
(Figure 1). 
Cardiac fibroblasts (CFB) are the most abundant cell type within the myocardium [8], 
which is critical in maintaining normal cardiac structure and ECM homeostasis [9-12]. In 
pathological remodeling, up-regulated CFB can result in excess matrix production and 
deposition of ECM proteins in the myocardium, such as collagen synthesis and deposition, 
which exerts adverse effects on cardiac structure and function [12-16]. In addition to being the 
primary source of ECM proteins, fibroblasts produce a number of cytokines, peptides and 
enzymes among which MMPs and tissue inhibitor of metalloproteinase (TIMPs) directly 
impact the ECM turnover and homeostasis [13-19]. Remodeling of the ECM plays a pivotal 
role in cardiac remodeling and is a key process determining the clinical course and outcome of 
cardiovascular diseases evolving with CHF. Recent research on the assessment and the tre-      




-atment of CHF patients has expanded from an initial focus on reducing hemodynamic load to 
interventions that potentially modify maladaptive cellular and molecular processes.  
Accumulating evidence shows that, in the pathophysiological process of CHF, molecular 
biomarkers could provide a unique avenue to potentially improve our capability of predicting 
adverse outcomes, to serve as novel drug targets, and moreover, help gauge therapeutic 
efficacy. Some 'traditional' biomarkers such as cardiac troponin, natriuretic peptides, and C-
reactive protein have been studied in the patients with CHF and are currently well-established 
parameters in clinical practice, respectively indicating the level of cardiac myocyte damage, 
inflammation, ventricular remodeling, myocardial injury and renal dysfunction that occurs in 
CHF [20, 21]. One such emerging biomarker is Galectin-3 (Gal-3), associated mainly with 
myocardial fibrogenesis, and which is properly studied in the present thesis.  
 
The characteristics of Gal-3 
 Gal-3 is a 29-35 kDa chimaera-type galectin belonging to the β-galactosidase binding 
lectins family, and is characterized by an extended N-terminal domain (110-130 amino acids) 
and a C-terminal carbohydrate recognition domain (CRD) (130 amino acids) [22, 23]. Gal-3 
communicates with a variety of ECM proteins, carbohydrates (e.g., N-acetyllactosamine) as 
well as unglycosylated proteins such as cell surface receptors (macrophage antigens CD11b/ 
CD18) and extracellular receptors (collagen IV) which, furthermore, modulates cell-cell adhe- 







-sion signaling in the extracellular compartment [24-27]. 
Gal-3 is expressed in various types of cells and tissues and is important in diverse 
physiological and pathological processes such as immune and inflammatory responses, tumor 
development and progression, neural degeneration, atherosclerosis, diabetes, as well as wound 
repair. Gal-3 has been detected in many proliferative cells including tumor cells, eosinophils, 
neutrophils, activated macrophages and fibroblasts [28-31] (Figure 2).  Notably, many of these 
cell types play active roles in the inflammatory response and the formation of fibrosis 
(fibrogenesis). Recent studies reveal that, as a multifunctional biomarker, Gal-3 plays a key 
role in the cardiac remodeling process by participating in ECM homeostasis and inflammation 
responses. [20] 
 
Gal-3 and its therapeutic implications  
Gal-3 was discovered around two decades ago [32]. It is widely distributed in several 
organs including the heart, lungs, liver and kidneys [33]. The role of Gal-3 in fibrosis and 
inflammation has been elucidated in recent years. In the healthy tissue, Gal-3 expression is 
absent or reduced. However, under pathological conditions, Gal-3 expression is substantially 
up-regulated, specifically in inflammation and fibrosis which are crucial in cardiac remodeling 
and renal fibrosis. In-situ hybridization and immunohistochemistry analyses show that Gal-3 
is highly distributed in the fibrotic area of myocardium and co-localizes with macrophages 
Figure 2. Glactin-3 is expressed in various cells and organs. 
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[34]. An ever-growing body of experimental evidence has found that macrophage-derived 
Gal-3 was associated with activated myofibroblasts and subsequently increased collagen 
synthesis and deposition, playing an important role in regulating extracellar matrix in the 
damaged tissue area [30, 31, 34-41]. 
The first evidence showing an involvement of Gal-3 in heart failure originates from a 
landmark study by Sharma and colleagues [34]. The researchers demonstrated Gal-3 as a new 
target for intervention in the CHF. Furthermore, Henderson et al demonstrated that Gal-3 
expression was markedly increased in progressive renal fibrosis. Gal-3 deficiency exhibited 
less renal inflammation, representing a lesser pro-fibrotic response with significant decreases 
in collagen production and deposition [30]. Additionally, Kalatjou et al. showed significantly 
increased Gal-3 expression in a kidney fibrosis model, which was amenable to a novel 
therapeutic strategy, Gal-3 inhibition, to attenuate fibrosis [42]. In addition to experimental 
studies, various clinical trials have also indicated a potential clinical utility of Gal-3 as a 
biomarker for prognosticating heart failure. Van Kimmenade et al firstly evaluated the 
prognostic and predictive value of Gal-3 as a biomarker in acute heart failure [43]. In 
PREVEND trial, they then demonstrated that high plasma Gal-3 levels were associated with 
all-cause mortality [44]. Furthermore, the DEAL-HF trial investigated the incremental value 
of Gal-3 over Nt-proBNP alone [45]. Finally, the HF-ACTION study revealed that Gal-3 was 
associated, yet not independent from NT-proBNP, with NYHA class II-IV, lower systolic 
blood pressure, increased creatinin, and lower maximal oxygen consumption [46]. 
In summary, macrophage-derived Gal-3 is associated with myofibroblast-induced 
collagen synthesis and deposition, playing a central role in pathophysiological cardiac 
remodeling and heart failure. 
 
The aim of this thesis 
 
As a multifunctional biomarker, Gal-3 plays an important role in detecting fibrogenesis 
and inflammatory processes, and is attracting widespread attention. Numerous studies have 
been elucidating the role of Gal-3 in the development of organ fibrosis, however, Gal-3 
targeted therapy in cardiac remodeling or renal dysfunction that occurs in CHF has been given 
less attention. 
This thesis will discuss the role of Gal-3 in fibrogenesis of cardiac remodeling and 
cardiac-related kidney disease. The main focus will be on Gal-3-related fibrogenesis in 
cardiovascular diseases. Chapter 2 and 3 of this thesis will describe the mapping of Gal-3 
pathways in the pathogenesis of cardiac remodeling in CHF and illustrate its potential 
therapeutic target in fibrogenesis by inhibiting collagen synthesis. The main question 
discussed in the above two chapters is: how does Gal-3 participate in cardiac remodeling as 
well as further influence heart failure progression. 
Chapter 1 
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To further address Gal-3 targeting as a potential therapeutic candidate in cardiac 
remodeling, chapter 4 focuses on whether genetically or pharmacologically inhibiting Gal-3 
can prevent or reverse cardiac remodeling. We will show how Gal-3 influences fibrogenesis 
by using different cardiac fibrosis models. Furthermore, since cardiovascular diseases are 
frequently accompanied with renal dysfunction, we will subsequently investigate Gal-3 
targeted intervention in a hypertensive rat model (chapter 5). Moreover, we will also discuss 
the correlations that exist between the plasma Gal-3 levels and renal dysfunction that occurs 
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Galectin-3 in Cardiac Remodeling 
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Galectin-3 is a member of the galectin family, which consists of animal lectins that bind 
β-galactosides. Recently, a role for galectin-3 in the pathophysiology of heart failure has been 
suggested. It was observed that galectin-3 is specifically upregulated in decompensated heart 
failure compared with compensated heart failure in animal models of heart failure. This has 
been associated with activation of fibroblasts and macrophages, which are a hallmark of 
cardiac remodeling. Therefore, galectin-3 may be a culprit biomarker in heart failure. Initial 
clinical observations indeed indicate that galectin-3 may be an useful biomarker for 
decompensated heart failure, with incremental value over well used “pressure-dependent” 
biomarkers like BNP. Future studies should be designed to deeper understanding of galectin-3 
biology, in order to better address the usefulness of galectin-3 as a biomarker and to probe if 
anti-galectin-3 therapy may be useful in treating heart failure. 
 
Keywords: Galectin 3; Heart failure; Prognosis; Fibrosis; Macrophages; Biomarkers; Renin; 




















Galectins are a family of lectins that bind β-galactosides [1,2]. Galectins are expressed in 
vertebrates like fish, birds, amphibians, and mammals, but also in invertebrates (worms, 
insects) and even in lower organisms like sponge and fungus [1,2], which suggest an 
important role in biology. Currently, 15 members of the galectin family have been described 
in vertebrates.  
All galectins bind carbohydrate via carbohydrate-recognition domains (CRDs) with many 
conserved sequence elements that are typically about 130 amino acids. Some galectins contain 
just one CRD (galectins 1, 2, 5, 7, 10, 11, 13, 14 and 15), others (tandem-repeat like) galectins 
contain two homologous CRDs in a single polypeptide chain, separated by a linker of up to 70 
amino acids (galectins 4, 6, 8, 9 and 12), while galectin-3 contains a non-lectin N-terminal 
region (about 120 amino acids) connected to a CRD and is often referred to as a chimera-like 
galectin. Each galectin has an individual carbohydrate-binding preference. Most galectins are 
bivalent or multivalent with regard to their carbohydrate-binding features: one-CRD galectins 
may form dimers; two-CRD galectins have two carbohydrate-binding sites; while galectin-3 
forms pentamers upon binding to multivalent carbohydrates. So galectins are capable of 
forming ordered “arrays” made of lectin and multivalent glycoconjugates [3,4].  
Galectins are primarily localized in the cytoplasm, but can also be localized in the 
nucleus). Galectins can be secreted, however they do so without a specific signal sequence. 
Galectin family members do not contain a classical signal sequence. Consistent with this 
feature, the proteins are localized primarily in the cytoplasm, although also in the nucleus 
under certain conditions. However, they can be secreted and thus belong to the group of 
proteins that do not contain a signal sequence but can function outside cells [5].  
Galectins may bind to different cell surface antigens and receptors, in a carbohydrate-
dependent manner. It has been suggested that galectins may not have specific individual 
receptors, but that each galectin can bind to a set of cell surface or extracellular matrix 
glycoproteins containing suitable oligosaccharides. Recent studies have demonstrated that 
galectins also exert intracellular functions, like signal transduction, by binding to intracellular 
ligands and participating in intracellular signaling pathways [6]. 
 
Galectin-3: Biology and expression 
Biology 
Galectin-3 (sometimes also referred to as Mac-2, CBP-35, εBP, RL-29, HL-29, L-34, or 
LBP; size: 31KDa) is found in solution as a monomer with two functional domains [7-9]. 
Galectin-3 is unique for having an extra N-terminal domain of about 100-150 amino acids 
long, rich in proline, glycine, tyrosine, and glutamine [10]. Galectin-3 has high affinity for 
lactose and N-acetyllactosamine; affinity for N-acetyllactosamine is about 5-fold higher than 
for lactose; ligands containing poly-N-acetyllactosamine sequences use galectin-3 as a 
Chapter 2 
24 
receptor. Galectin-3 is an unique chimera-like galectin. This means galectin-3 consists of 
carbohydrate recognition ánd collagen-like domains which makes it capable to interact with a 
wide array of extracellular matrix proteins, carbohydrates (such as N-acetyllactosamine) and 
unglycosylated molecules, such as cell surface receptors (macrophage CD11b/CD18) and 
extracellular receptors (collagen IV). Galectin-3 mainly binds to glycosylated proteins of the 
matrix, including laminin, fibronectin and tenascin [11,12]. This has extensively been 
reviewed by Krzeslak et al. and Ochieng et al – see the adapted Table 1 [10,13]. 
 
Table 1. Ligands for galectin-3  
 Ligand Source /Cells 

























Human T lymphoma 
Jurkat cells 









Murine T3 fibroblasts 
HL60 
Human T Lymphoma 
Jurkat cells 




Others AGE Ubiquitious 
AGE advanced glycation end products; CBP70 glucose-binding protein; EHS Engelbroth-Holm-Swarm tumor 
laminin; LAMP lysosomal-associated membrane protein 1; M2BP Mac-2 binding protein; MAG myelin-
associated glycoprotein; MP20 membrane protein 20; NCAM neural cell adhesion molecule (adapted from 
Krzeslak [10]). 
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Galectin-3 is localized in the cytoplasma and the nucleus. Loss of nuclear galectin-3 is 
believed to affect the malignant phenotype of cancers. Nuclear expression of galectin-3 is 
associated with proliferative effects and it has been described that galectin-3 translocates from 
the cytosol into the nucleus via a passive and an active pathway [14]. Galectin-3 contains 
several phosphorylation sites and other determinants important for the secretion of galectin-3, 
which goes via a novel, non classical pathway [15].  
Through its interaction with extracellular matrix proteins galectin-3 is able to cross the 
plasma membrane despite its lack of appropriate signal peptides; secretion of galectin-3 is 
critically regulated at the plasma membrane [16].  
 
Expression of Galectin-3 
The different members of the galectin family exhibit a specific pattern of expression in 
various cells and tissues. Expression of galectin-3 has been detected in macrophages, 
eosinophils, neutrophils, and mast cells [17,18]. In tissues, galectin-3 is most abundantly 
expressed in lung, spleen, stomach, colon, adrenal gland, uterus and ovary [19]. Galectin-3 is 
also expressed, albeit at a much lower level, in kidney, heart, cerebrum, pancreas, and liver 
[19]. However, under pathophysiological conditions, the level of expression of gelactin-3 may 
change substantially so that a low constitutive expression level of galectin-3 does not preclude 
a prominent function, e.g. in liver and heart.  
    Galectin-3 contains several phosphorylation sites and other determinants important for the 
secretion of galectin-3, which goes via a novel, non classical pathway [15]. Secretion of 
galectin-3 is critically regulated at the plasma membrane [16].  
 
Galectin-3 in Cardiac Remodeling and Heart Failure 
Experimental observations 
The observation that galectin-3 is increased in decompensated heart failure has been 
published in a seminal paper by Sharma [20]. The authors studied homozygous REN2- rats 
that overexpress the murine2-d renin gene, resulting in severe hypertension with end-organ 
damage [21-22]. It was observed that while some rats go into overt failure after about 15 
weeks, with signs of heart failure like dyspnea, lethargy and severely compromised 
hemodynamics, some rats remain compensated. These two groups were compared using a 
cDNA array with whole RNA from the rat hearts. It was observed that a set of 48 genes were 
differentially regulated [20,23]. Interestingly, most of the differentially regulated genes 
typically encoded matricellular proteins, like collagens, osteoactivin and fibronectin, but not 
loading-dependent factors like natriuretic peptides [23]. Galectin-3 was the strongest regulated 




To dissect cause from consequence, Sharma and colleagues showed that infusion with 
galectin-3 in the pericardial sac of normal rats led to the development of cardiac remodeling 
with dysfunction and increased expression of collagens. Given the upregulation of galectin-3 
well before the transition to overt heart failure, the authors concluded that galectin-3 may be 
factor that should be considered as a novel target for intervention in heart failure. 
A recent paper by Thandavarayan [24] described a model with cardiospecific expression 
of a dominant-negative form of 14-3-3 protein, which regulates apoptosis and several 
signaling pathways that leads to LV dysfunction. Besides typical changes for LV remodeling, 
like hypertrophy, fibrosis, and apoptosis, the authors also describe an upregulation of galectin-
3 in the LV [24]. So, upregulation of galectin-3 may be a general phenomenon in LV 
dysfunction and not be confined to models with increased AngII signaling. 
A potential role in mediating the effects of galectin-3 has been suggested for N-acetyl-
Ser-Asp-Lys-Pro (ac-SDKP), a tetrapeptide degraded by angiotensin-converting enzyme 
(ACE) by the group of Carretero [25,26]. First, they showed that differentiation of murine 
bone marrow cells to macrophages was inhibited by ac-SDKP. Second, in mice treated with 
AngII, ac-SDKP reduced fibrosis and expression of galectin-3 in left ventricular tissue [25]. In 
a second study, LV remodeling was induced by infusion of galectin-3 in the pericardial sac 
[26], with or without the co-administration of ac-SDKP. Like in the initial report by Sharma 
[20], galectin-3 enhanced macrophage and mast cell infiltration which is associated with 
interstitial and perivascular fibrosis and LV dysfunction. Ac-SDKP prevented these events, in 
whole or in part, and these effects were shown to be mediated by TGF-β/Smad3 pathway. 
 
Fibrosis 
Galectin-3 seems to be particularly involved in fibrosis. Fibrosis and scar formation are 
pivotal processes in maladaptive cardiac remodeling. Fibroblasts, myofibroblasts, and 
macrophages have been identified as important cells in the initiation and progression of tissue 
scarring [27-29]. Various fibrotic conditions are associated with up-regulation of galectin-3: 
liver cirrhosis [30,31], idiopathic lung fibrosis [32], and chronic pancreatitis [33]. In animal 
models upregulation of galectin-3 has been described for hepatic [31], renal [34-36], and 
cardiac [20,25,26] fibrosis.  
More detailed study into the role of galectin-3 in cardiac remodeling revealed that 
galectin-3 was localized at the very sites of fibrosis, colocalizing with fibroblasts and 
macrophages, but not with cardiomyocytes. Galectin-3 binding sites were visualized by 
biotynalyted antibodies and localized predominantly to fibrotic areas [20], in line with the 
evidence that galectin-3 binds extracellular proteins. Furthermore, recombinant galectin-3 
causes proliferation and collagen production of cultures cardiac fibroblasts in vitro. Other 
published data corroborate these observations [25,26].  
Galectin-3 has also been identified as a potentially important mediator of removal of 
advanced glycosylation end-products (AGEs) [37]. AGEs are molecules formed during a non-
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enzymatic reaction between proteins and sugar residues, and accumulate in the human body 
with age, but also with enhanced states of oxidative stress, an increased intake of AGEs, and 
renal and heart failure, and are thought to contribute to myocardial stiffening [38]. An AGE-
specific cellular receptor complex (AGE-R) mediating AGE removal has been described. 
Galectin-3 interacts with AGE-R components thus contributing to the elimination of these 
pathogenic substances. Galectin-3 disruption is associated with increased susceptibility to 
AGE-induced renal disease, which indicates that galectin-3 is operating in vivo as an AGE 
receptor to afford protection toward AGE-dependent tissue injury [39,40]. Whether galectin-3 
acts on AGE biology in the heart remains unknown. 
Other experimental lines of evidence provide further compelling evidence that galectin-3 
is a key player in fibrosis. Especially the generation of galectin-3 deficient mice has been 
instrumental in the study of galectin-3 in fibrosis. The group from Sehti has published papers 
on the role of galectin-3 in hepatic and renal fibrosis [31,35]. In the liver, TGF-β via galectin-
3 activates myofibroblasts. In the kidney, galectin-3 expression and secretion by macrophages 
is a major mechanism in renal fibrosis. 
 
Inflammation 
Besides fibrosis, galectin-3 plays an important role in the inflammatory response, which 
is an important player in the process of cardiac remodeling [41]. In renal models of 
inflammation, galectin-3 has been convincingly linked to fibrosis and damage [34,36]. 
Employing a model of murine renal fibrosis, Henderson and colleagues established that 
depletion of macrophages significantly reduced myofibroblast activation and decreased 
fibrosis [35]. In the heart, no direct evidence exists has been generated for inflammatory 
effects via galectin-3, although in Sharma’s paper besides galectin-3 other genes encoding for 
immune factors were differentially regulated [20]. Mice which constitutively express IFN-
gamma in their livers develop myocarditis with macrophages expressing high levels of 
galectin-3 [42].  
 
Clinical Studies 
The first report in human subjects was the paper by Sharma et al. [20]. They studied 
ventricular biopsies from patients with aortic stenosis with preserved or depressed ejection 
fraction and showed that gealctin-3 was upregulated in the biopsies from patients with 
depressed ejection fraction. Van Kimmenade et al. [43] published the first clinical study that 
evaluated the potential role of galectin-3 as a plasma biomarker in heart failure. In this study, 
599 acutely dyspneic subjects were evaluated with the goal to establish the usefulness of NT-
proBNP, galectin-3 and apelin in diagnosing heart failure and predicting outcome. A blood 
sample was collected at baseline, and NT-proBNP, galectin-3 and apelin were measured later. 
A total of 209 patients were diagnosed with heart failure. NT-proBNP came up as the most 
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powerful predictor for diagnosing heart failure. ROC analysis examining the value of NT-
proBNP for the diagnosis acute heart failure showed an area under the curve (AUC) for NT-
proBNP of 0.94 (P<0.0001), while the AUC for galectin-3 for the diagnosis acute heart failure 
was 0.72 (P<0.0001) – the difference between NT-proBNP and galectin-3 being highly 
significant (P<0.0001). The optimal cut-off of galectin-3 in this study was 6.88 ng/mL, which 
resulted in a reasonable sensitivity of 80% but a poor specificity of 52% [43]. For predicting 
short term prognosis (60 days, primary endpoint rehospitalization due to heart failure (N=60) 
or all cause mortality (N=17), gealectin-3 was the most powerful predictor: an AUC for 
galectin-3 of 0.74 (P=0.0001) and an AUC for NT-proBNP of 0.67 (P=0.009); the difference 
being borderline significant (P=0.05). In multivariate analysis, galectin-3 was the strongest 
predictor for death and the combination of death and rehospitalizations for heart failure. 
Remarkably, well known predictors for outcome like NT-proBNP and renal function were not 
predictive in this study. Nevertheless, this study provides strong support for the exploration of 
galectin-3 as a biomarker that may predict prognosis, while its usefulness in detecting heart 
failure or adding incremental value (over currently used clinical correlates and NT-proBNP) 
in the diagnostic work-up of heart failure remains unclear.   
In a larger study in patients with chronic heart failure, Lok et al. [44] showed that 
galectin-3 predicts long-term outcome (mean follow-up: 3.4 years); HR 1.95, CI 1.24-3.09, 
P=0.004). In this study, not many other biomarkers of heart failure were measured, so that is 
impossible to value the precise role of galectin-3 in this cohort. 
An interesting mechanistic study by Milting and colleagues [45] describes the kinetics of 
galectin-3 in 55 patients with end stage heart failure with the need for mechanical circulatory 
support or MCS. In this small study several biomarkers, especially related to myocardial 
fibrosis and remodeling, were determined. First, the fibrosis-related biomarkers including 
gelaectin-3 were increased compared with controls. Second, the authors reported that none of 
the fibrosis-related biomarkers like TIMP1, tenascin, osteopontin or galectin-3 were reduced 
by MCS; only the loading-related biomarker BNP was reduced by MCS. Third, patients who 
did not survive while on MCS compared with patients who lived until transplantation had 
higher baseline galectin-3 levels.  
A recent study by Lin et al. [46] describes the relation between serum galectin-3 and 
markers of extracellular matrix turnover. They studied 106 patients with chronic heart failure 
(NYHA class II-III, mean LVEF 35±9%). Serum aminoterminal propeptide of procollagen 
(type I, PINP) and type III (PIIINP), matrix metalloproteinase-2(MMP-2) and tissue inhibitor 
of metalloproteinase-1 (TIMP-1) were analyzed, along with galectin-3. Galectin-3 was 
correlated with PIIINP, TIMP-1, MMP-2, but not with LVEF, age and sex. After correction, 
the correlation between galectin-3 and PIIINP and MMP-2 remained statistically significant. 
The authors conclude these findings suggest a relationship between gelactin-3 and 
extracellular matrix turnover.  
Taken together, from available clinical data, plasma and/or serum galectin-3 is increased 
in acute and chronic heart failure. It seems that galectin-3 may be of particular value to predict 
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prognosis, as for clinical diagnosing and/or decision making it seems less powerful, although 
we do not have sufficient data available.   
 
Conclusions 
Galectin-3 is interesting and complex protein with many effects in many organs. In the 
failing or stressed heart, it has been shown that activated macrophages secrete galectin-3. The 
increased expression levels of galectin-3 are associated with the tendency to develop 
decompensated heart failure, and in clinical cohorts, increased plasma galectin-3 levels are 
linked with worse prognosis. Therefore, galectin-3 may be advocated as a novel biomarker, 
but it may also be in the pathophysiological circle of heart failure (“culprit biomarker”), and 
therefore it may also be target for intervention [47]. The suggested pathways of galectin-3 are 
displayed in figure 1 [47].  
 
Figure 1. Galectin-3 pathways. The network represents molecular relationships between different gene products. Node 
shapes indicate the functional class of the gene product while node colours indicate a role in general fibrosis (orange) or 
cardiac fibrosis (green). Edge colurs indicate up-regulation or activation (red), down-regulation or inhibition (green) or 
involvement without clear directionality (yellow). All relationships are supported by references from the ingenuity Pathway 
Knowledge Base or key reference included in the review by de Boter et al. [47]. Figure and legend reprinted with permission 
of the publisher (Oxford Journals; Eur J Heart Fail.2009, 11:811-817). 
 
There are several fields of uncertainty. First, we do not know how galectin-3 is regulated 
at a transcriptional and translational level in the heart. Mechanistic studies have provided 
evidence that cardiac fibroblasts and macrophages are the main sources for galectin-3, and 
that the TGF-β/smad pathway is involved. Inflammatory signals also contribute in the 
regulation of galectin-3. However, what precise signals govern the production and secretion of 
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galectin-3 remains largely enigmatic. Second, although several lines of evidence strongly 
suggest a contributory role for galectin-3 in the pathophysiology of heart failure, we lack 
proof-of-principle experiments, e.g. in galectin-3 deficient mice or in pharmacological studies, 
to show that galectin-3 is unequivocally contributing to the onset and progression of cardiac 
remodeling. Finally, we have no data if therapy, or what therapy, may affect galectin-3 
expression and signaling.  
Taken together, from available clinical data, plasma and/or serum galectin-3 is increased 
in acute and chronic heart failure. It seems that galectin-3 may be of particular value to predict 
prognosis in HF; the cause for clinical diagnosing and/or decision making is less convincing; 
to date we do not have data available to support the use of galectin-3 for this purpose. Parallel 
to the experiments described by Sharma [20], we have observed that galectin-3 is upregulated 
in compensated and decompensated hypertrophy when compared with healthy control rats, 
however the difference is of lesser extent than when comparing the decompensated versus the 
compensated rats (de Boer, unpublished data). This suggests that galectin-3 may be of lesser 
importance during the early stages of the disease. Furthermore, no data on serial 
measurements of galectin-3 have been published. So, we lack data on half-life, kinetics, 
clearance and other parameters of galectin-3 biology. The study from Milting [45] suggests 
that acute unloading by MCS only reduces typical “loading” biomarkers, i.e. BNP (or NT-
proBNP), not so much biomarkers associated with turnover of the extracellular matrix, 
including galectin-3. Most treatment modalities in heart failure however, are not acute 
interventions but chronic pharmacological neurohormonal inhibition [48]. However, if such 
long term treatment aimed at reduction of matrix apposition and fibrosis, like ACE-inhibition 
and aldosteron receptor blockers will result in lowering of galectin-3 levels is currently 
unknown and warrants further study.  
If it is indeed proven that standard treatment of heart failure is associated with lowering 
of galectin-3 expression and levels, one could argue that galectin-3 itself could also be a target 
for therapy. Specific agents targeted against galectins have been tested in small trials with 
cancer patients. These agents have not been evaluated in experimental or clinical heart failure, 
but will likely be tested momentarily for their value in this devastating disease.  
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Myocardial injuries stemming from pressure overload or myocardial infarction lead to 
cardiac remodeling and represent major health problems world-wide.  An ever accumulating 
body of experimental and clinical research appoints galectin-3, a β-galactoside-binding lectin, 
as a key player in this maladaptive response to myocardial injury. Herein, a specific role for 
galectin-3 in inflammation and fibrogenesis has been elucidated in experimental and clinical 
studies.  Galectin-3 was first associated with pathological conditions leading to cardiac 
remodeling, such as inflammation and fibrosis. Then, as the carbohydrate recognition domain 
of galectin-3 reacts with glycosylated proteins such as laminin, fibronectin and tenascin, a 
multifunctional role of galectin-3 in the extracellular matrix was postulated. Notably, 
experimental animal studies clearly showed that galectin-3 is a mediator of crucial steps in 
fibrogenesis, and further induces cardiac inflammation, hypertrophy and dysfunction. Possible 
mechanisms pertaining to galectin-3 inflammatory and fibrotic properties have been suggested 
to involve macrophage activation, galectin-3-induced chemotaxis and activation of the TGF- 
β-Smad3 signaling pathways. Additionally, the link between plasma galectin-3 and fibrosis 
was also established in clinical biomarker studies. Galectin-3 and its pathways may be 
explored further in order to develop more efficient strategies to target cardiac remodeling in 
heart failure leading to fibrosis.   
 




















Role of Galectin-3 Pathways in the Pathogenesis of Cardiac Remodeling and Heart Failure 
39 
3 
STRUCTURE, EXPRESSION AND FUNCTION OF GALECTIN-3  
Galectin-3 is a 29-35 kDa chimaera-type galectin. Galectins form a large family of 
galactosidase binding lectins, but galectin-3 is the only member of the galectin family with an 
extended N-terminal domain (110-130 amino acids). This N-terminal domain is composed of 
tandem repeat sequences comprising nine amino acid residues and is connected to a C- 
terminal carbohydrate recognition domain (CRD) of about 130 amino acids [1, 2]. The CRD 
interacts with various glycosylated proteins, modulates cell-cell adhesion and cell signaling in 
the extracellular compartment [1]. Further, the galectin-3 CRD and collagen-like domains 
communicate with a variety of extracellular matrix proteins (ECM), carbohydrates (e.g., N-
acetyllactosamine), and also unglycosylated proteins such as cell surface receptors 
(macrophage antigens CD11b/CD18) and extracellular receptors (collagen IV) [3-6], and they 
furthermore modulate cell-cell adhesion and cell signaling in the extracellular compartment. 
Galectins are expressed in various cells and tissues and are important for diverse 
physiological and pathological processes, such as immune and inflammatory responses, tumor 
development and progression, neural degeneration, atherosclerosis, diabetes, as well as wound 
repair. Galectin-3 has been detected in many proliferative cells including tumor cells, 
eosinophils, neutrophils, and activated macrophages [7, 8].  Notably, many of these cells types 
are operative in the inflammatory response and the formation of fibrosis (fibrogenesis). 
Galectin-3 is predominantly located in the cytoplasm. While intracellular galectin-3 plays 
a pivotal role in diverse cell growth, anti-apoptosis signaling, and mRNA splicing, 
extracellular (or cell surface bound) galectin-3, on the other hand, participates in cell-cell and 
cell-matrix adhesion, by binding to glycosylated ECM components, including laminin, 
fibronectin, tenascin, and Mac-2 binding protein [3, 4, 9-12].  Thus, extracellular galectin-3 
appears in tight communication with factors involved in fibrogenesis. 
Differential expression of galectin-3 has been reported for different murine organs. 
Herein, lower expression was found in cerebrum, heart, and pancreas, while moderate 
expression was found in liver, ileum, kidney and adrenal gland and high expression in lung, 
spleen, stomach, colon, uterus, and ovary [13]. Figure 1 displays an overview of galectin-3 
distribution in various healthy tissues of different species – our data are in concert with results 
published by Kim and colleagues [13].  Notably, a growing body of evidence reveals that high 
expression levels of galectin-3 are closely associated with pathological conditions, specifically 
conditions pertaining to inflammation and fibrosis which are also key conditions in cardiac 
remodeling. 
 
Localization of galectin-3 in damaged tissue   
Inflammation and fibrosis are intertwined pathological states and galectin-3 has 
consistently been observed to be involved in these damage states. 
Galectin-3 is not only secreted by activated macrophages but in situ hybridization and 




Figure 1: Immunohistochemical localization, protein and mRNA expression of galection-3 in various tissues of 
different species. Galectin-3 immunoreactivity has been observed in heart (A), Lung (B), Liver (C), Spleen (D), 
and Kidney (E). F-I: Galectin-3 protein expression (assessed by Western blot) and mRNA expression (assessed 
by qPCR) has been predominantly observed in (mouse, rat, human) lung, testis/ovary, spleen, prostate, adipose 
tissue en skin. Picture A – E reprinted from reference [13] with permission from the publisher; Figure F – I: 
unpublished data (Yu et al.). Scale bars, 50 µm ( A and B); 60 µm (C); 90mm (D); 400 µm(E). 
 
area of myocardium and co-localizes to macrophages [14]. Moreover, an ever growing body 
of experimental evidence found that galectin-3 manifests in various damaged tissue, in 
particular in tissues with increased collagen deposition and localization in the fibrotic area 
[14-23]  Further, galectin-3 was expressed in proliferating fibroblast and was also found in 
nucleus when cells were exposed to apoptotic stimuli in vitro [24]. Moreover, galectin-3 
expression has been detected in isolated cardiac fibroblast to localize galectin-3 binding sites. 
Interestingly, contrary to cardiac fibroblast, galectin-3 binding sites were absent from 
cardiomyocytes [7, 8, 14, 25-27]. 
 
GALECTIN-3 IN EXPERIMENTAL FIBROSIS 
Early experimental support in liver, kidney and lung fibrosis 
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A prominent role for galectin-3 in fibrogenesis has been elucidated in recent years. Herein, 
work has specifically described fibrotic states in the liver, kidneys, pancreas and lungs.  For 
example, galectin-3 showed to be temporarily and spatially associated with fibrosis with a 
minimal expression in healthy rat liver, while highest expression was found at peak fibrosis 
and virtually no galectin-3 expression was present after recovery from fibrosis [19]. Then, 
galectin-3 deficiency in bile duct ligated (BDL) rats was recently shown to significantly 
diminish BDL induced hepatic TGF-β1 and procollagen expression and associated hepatic 
fibrosis [28]. Additionally, in a murine model of cirrhosis, bone marrow cell transplantation 
significantly decreased liver fibrosis which was associated with decreased hepatic galectin-3 
expression [29]. A recent report by Mackinnon et al [23] extended the involvement of 
galectin-3 to fibrosis in the lung. Authors found a significantly reduced TGF-β1 and 
bleomycin-induced lung fibrosis in galectin-3 deficient mice.  
Likewise, galectin-3 expression and secretion by macrophages has been identified as a 
major contributor to renal fibrosis. Mice with galectin-3 deficiency did not show macrophage 
recruitment upon interferon-gamma/LPS stimulation [19]. Henderson et al. also observed that 
galectin-3 mediated TGF-β induced myofibroblast activation, a crucial step in the fibrogenesis 
cascade [17].  Lastly, the therapeutic potential of targeting galectin-3 to relieve fibrotic burden 
has recently been investigated by Kolatsi-Joannou and colleagues [30] who demonstrated that 
folic acid induced kidney fibrosis and associated galectin-3 expression was significantly 
reduced by 1% treatment with modified citrus pectin (MCP). MCP is a pectin derivative 
binding to the galectin-3 CRD thereby inhibiting galectin-3 aforementioned effects. 
Altogether, a growing body of literature consistently supports a role of galectin-3 in 
fibrogenesis. This appears a generalized effect, not confined to one organ. 
Fibrosis is also central to the maladaptive response to myocardial injury, such as pressure 
overload and myocardial infarction leading to cardiac remodeling [14, 21, 22] Supporting the 
notion that galectin-3 constitutes a global player in fibrogenesis, it is not surprising  that  
galectin-3 has also been shown to be involved in myocardial fibrogenesis. 
 
Galectin-3 in cardiac remodeling pathway – recent experimental support 
The first evidence showing an involvement of galectin-3 in heart failure stems from a 
landmark study of Sharma and colleagues [14]. In a comprehensive microarray study galectin-
3 was identified as the most robustly overexpressed gene in heart-failure prone hypertrophied 
hearts compared to functionally compensated hearts in homozygous transgenic TGFmRen2-
27(Ren-2) rats. Ren-2 rats overexpress the mouse Ren-2d renin gene and spontaneously 
develop heart failure after 13-15 weeks. Further, continuous low-dose infusion of recombinant 
galectin-3 into the pericardial sac caused left ventricular dysfunction in healthy Sprague-
Dawley rats, associated with collagen deposition and other signs of cardiac remodeling [14]. 
These initial observations warranted galectin-3 to be considered as a new target for 
intervention in heart failure. 
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Then, more recently, Sharma et al [21] found a significant and high expression of 
galectin-3 in cardiac tissue of Ang-II induced hypertension in mice.  In this model, galectin-3 
was released by infiltrating macrophages in the myocardium and led to interstitial collagen 
deposition. Treatment with N-Acetyl-Ser-Asp-Lys-Pro (Ac-SDKP), an endogenous 
tetrapeptide specifically degraded by angiotensin converting enzyme (ACE), reduced 
macrophage activation and galectin-3 expression herein, and prevented  galectin-3-induced 
cardiac inflammation, fibrosis and remodeling.   
Additionally, Liu et al showed that in galectin-3-induced cardiac remodeling, galectin-3 
increased the number of macrophages, mast cell infiltration and activated the TGF β/Smad3 
pathway.  Ac-SDKP partially or near completely prevented galectin-3 induced cardiac 
inflammation, fibrosis, hypertrophy and dysfunction, possibly by inhibition of the TGF-
β/Smad3 signaling pathway [22].     
Recent studies by Thandavaryan et al. [31], Kamal et al. [32] and by Psarras et al. [33] 
further reveal a specific association of galectin-3 with left ventricular dysfunction and fibrosis. 
Specifically, Thandavaryan et al [31] found a significant increase in myocardial hypertrophy 
and fibrosis, as well as apoptosis, all associated with up-regulated galectin-3 in 14-3-3η 
protein mutant (DN-14-3-3η) mice after induction of diabetes. 14-3-3η protein has a 
regulatory role in apoptosis, adhesion, cellular proliferation, differentiation, survival and 
signal transduction pathways  [34]. As the authors stated, up-regulated galectin-3 appears to 
be a general phenomenon in LV dysfunction [31]. Moreover, Kamal et al. [32] demonstrated 
that cardiac hypertrophy, progressive fibrotic cardiac remodeling with increased collagen 
deposition were accompanied with significantly increased galectin-3 expression in 
cardiomyopathic hearts in a rat model of myosin-induced experimental autoimmune 
myocarditis (EAM). Notably, herein galectin-3 over-expression was dramatically reduced by 
treatment with T-3999, a novel phenylpyridazinone, indicating an inhibitory function of T-
3999 on galectin-3. 
Then, Psarras et al. [33] found that desmin deficient (des-/-) mice exhibit marked 
myocardial degeneration and fibrosis, which were associated with osteopontin (OPN) and 
galectin-3 overexpression (226x for OPN and 26x for galectin-3). OPN, like galectin-3, has 
chemotactic properties and is thus recruited to inflammatory sites [35, 36]. Psarras et al. [33] 
further compared des-/- OPN -/- mice with des-/- OPN +/+ mice and found that des-/- OPN -/- 
mice not only displayed remarkable improvements in ventricular function (53%) but also in 
myocardial fibrosis (44%) while also significantly reducing galectin-3 gene expression (by 
≈80%) compared to des-/- OPN +/+ mice, indicating that the observed diminished 
inflammatory and fibrotic response in OPN deficient des-/- mice could be partly explained by 
the significant reduced myocardial galectin-3 level [33]. 
So, accumulating experimental evidence implicates a role of galectin-3 in the 
development of organ fibrosis. Whether galectin-3 is a potential therapeutic target in left 
ventricular (LV) remodeling and heart failure is unknown. We have conducted experimental 
studies and our results suggest galectin-3 may a target for therapy. Genetic disruption and 
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pharmacological inhibition of galectin-3 attenuated adverse LV remodeling, fibrosis and 
subsequent HF development.  We perturbed mice with angiotensin II (AngII) and transverse 
aortic constriction (TAC) causing LV hypertrophy, decreased LV contractility and increased 
LV end-diastolic pressure, associated with increased fibrosis in wild type (WT) mice. 
However, galectin-3 knock out (Gal3-KO) mice did not develop LV dysfunction and fibrosis. 
Additionally, in homozygous TGR(mREN)27 rats, pharmacological inhibition of galectin-3 
with an oligosaccharide almost completely prevented LV dysfunction and fibrosis [54, 55]. 
This indeed suggests that drugs binding to galectin-3 may be potential therapeutic 
candidates for the prevention of heart failure with extensive fibrosis. It remains unclear what 
mechanisms underpin these effects. 
 
ROLE OF GALECTIN-3 IN MODULATION OF FIBROSIS 
Potential mechanism of galectin-3 in extracellular matrix 
Fibroblasts, myofibroblasts and macrophages have been identified as important cells in 
the initiation and progression of fibrogenesis, scar formation, and tissue remodeling [37-39]. 
Extracellular matrix remodeling (ECM) is a crucial aspect in fibrogenesis and galectin-3 
seems to play a multifunctional role in the ECM environment, as its CRD reacts with 
glycosylated proteins in the ECM, such as laminin, fibronectin, tenascin [3, 4], as well as 
membrane proteins, such as αM/β2 (CD11b/18) [40].  
 
Potential mechanisms of galectin-3 in myofibroblast differentiation 
Fibroblast to myofibroblast differentiation and activation by inflammatory cytokines, like 
TGF-β, preceded by influx of cells such as macrophages are some of the initial steps in the 
process of fibrogenesis.  A large body of research supports a role for galectin-3 in this process. 
 Herein, it appears that macrophages and TGF-β induce myofibroblast activation via galectin-
3, but that macrophage recruitment and TGF-β expression is independent of galectin-3. 
First, galectin-3 was visualized in the fibrotic area co-localizing with fibroblasts and 
macrophages [14]. Second, it was shown that infusion of recombinant galectin-3 into 
pericardial sac leads to inflammatory cell infiltration, cardiac fibroblast proliferation, collagen 
synthesis and deposition, essentially contributing to interstitial and perivascular fibrosis [14, 
21, 22]. Then, Dvorankova et al. demonstrated myofibroblast activation in vitro upon 
treatment with a moderately high dose recombinant galectin-3 [41]. Further, galectin-3 
deficiency significantly reduced myofibroblast activation in carbon tetrachloride (CCL4) 
induced hepatic fibrosis and renal fibrosis (in a model of unilateral ureter obstruction, UUO) 
[17, 19].  
Then, macrophages regulate fibroblast and myofibroblast activation in ECM and 
macrophage derived galectin-3 presents in various fibrotic pathologies. Injured tissue displays 
a marked increase in galectin-3 expression by activated macrophages and also an increased 
TGF-β expression, all these factors promote fibroblast proliferation and myofibroblast 
activation [17]. Macrophage depletion, then, significantly inhibits myofibroblast activation 
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and decreases fibrosis [19].  For example, Henderson and colleagues showed that galectin-3 
deficient macrophage recruitment could not drive myofibroblast accumulation and activation.  
Utilizing a cross-over experiment with wild-type or galectin-3 deficient macrophage 
supernatant and galectin-3 deficient renal fibroblast, these authors further observed that 
proliferation of galectin-3 deficient renal fibroblasts were activated by wild-type macrophages 
and attenuated by a galectin-3 inhibitor bis-(3-deoxy-3-{3-methoxybenzamido}-β-D-
galactopyranosyl-sulfane), while galectin-3 deficient macrophages did not induce proliferation 
in galectin-3 deficient renal fibroblasts. 
On the other hand, galectin-3 deficiency markedly reduces activated myofibroblast but 
does not affect macrophage recruitment nor pro-inflammatory cytokine profiles in injured 
tissue, such as IL-6 and TNF-α.  Additionally, while galectin-3 deficiency led to reduced 
collagen deposition and reduced myofibroblast activation, TGF-β expression or smad2/3 
phosphorylation were not influenced [19].  
Furthermore, our unpublished galectin-3 chemotaxis assay results show that recombinant 
galectin-3 significantly induces monocyte migration, which could be markedly attenuated after 
treatment with galectin-3 inhibitors including modified citrus pectin (MCP) and lactose. These 
inhibitors act as a ligand, binding to galectin-3’s CRD. 
Altogether, these events clearly indicate galectin-3 to be a key player in the signal axis of 
fibrosis generation, specifically inducing macrophage and TGF-β induced myofibroblast 
activation [17, 19, 23, 42].  
 
CLINICAL UTILITY OF GALECTIN-3 
Clinical trials have consistently indicated a potential clinical utility of galectin-3 as a 
biomarker for prognosticating heart failure. Herein, van Kimmenade et al. were the first to 
evaluate the prognostic and predictive value of galectin-3 as a biomarker in acute heart failure 
[43], in the Pro-BNP investigation of dyspnea in the emergency department (PRIDE). While 
N-terminal pro brain natriuretic peptide (NT-proBNP) was a superior predictor for diagnosis 
of acute heart failure compared to galectin-3 and apelin (herein galectin-3 was a better 
predictor than apelin)  Figure 2A, galectin-3 was the superior predictor compared to NT-
proBNP and apelin for prognosis in acute heart failure. Multivariate logistic regression 
analysis revealed that elevated plasma levels of galectin-3 were indeed the most powerful 
predictor for death, or the combination of death and recurrent heart failure within 60 days.  
Plasma galectin-3 levels were related to detailed echocardiographic examinations in 
substudy (N =115) of the PRIDE [44]. Galectin-3  levels were not strongly related to markers 
of LV structure or systolic function, but related to measures of RV function and diastolic 
dysfunction, and highest galectin-3 concentrations were strongly associated with a higher risk 
of 4 year mortality, is independent from LV dimensions, function, and RV pressure, 
supporting the role galectin-3 may play in fibrosis and progressive cardiac failure. 





Figure 2 Galectin-3 as a biomarker; data from several clinical trials.  
Figure 2A: Combined receiver-operating characteristic (ROC) curves for amino-terminal pro-brain natriuretic 
peptide (NT-proBNP), galectin-3 and apelin for the diagnosis of heart failure in dyspneic patients. The ROC 
analysis for NT-proBNP showed an area under the curve (AUC) for NT-proBNP of 0.94 (p = 0.0001). The ROC 
analysis for galectin-3 showed an AUC of 0.72 (p = 0.0001). The AUC for apelin for diagnosis of acute heart 
failure was 0.52 (p = 0.23). This figure was reprinted from van Kimmenade et al. [43], with permission. 
Figure 2B: Mortality as a function of baseline galectin-3 and NT-proBNP categories. The median value of NT-
proBNP (253 pmol/L), was used to define two levels of NT-proBNP concentration. Of the 232 subjects, 231 had 
both a galectin-3 and NT-proBNP measurement. The number of patients in the each category is as follows: high 
galectin-3 and high NT-proBNP (n=66); low galectin-3 and low NT-proBNP (n=69); low galectin-3 and high 
NT-proBNP (n=49); high galectin-3 and low NT-proBNP (n=47). Reprinted from reference [46] by Lok et al., 
with permission.  
Figure 2C: Graphical depiction of the risk estimates for experiencing the primary outcome in patients with 
HFPEF and HFREF with increasing levels of plasma galectin-3. The distribution of (log-transformed) galectin-3 
is depicted in the background in brown bars. A similar increase in galectin-3 causes a much more pronounced 
increase in risk in patients with HFPEF compared to patients with HFREF.  Figure reprinted from reference [47] 
by de Boer et al, with permission.Figure 2D: Graph showing galectin-3 levels in male (blue line) and female 
subjects (red line) from the general population. Grey-shaded areas indicate 95% confidence intervals. Galectin-3 
levels increase with increasing age, particularly in female subjects. This figure is reprinted from reference [49] by 
de Boer et al, with permission. 
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Further and specifically relating galectin-3 to fibrosis, plasma galectin-3 levels were 
significantly correlated with several serum markers of cardiac ECM turnover, such as PIIINP,  
MMP-2 and TIMP-1, in 106 patients with chronic heart failure (New York Heart Association 
class II-III; mean LV ejection fraction [LVEF], 35+9%) [45].  Subsequently, Milting et al. 
described the kinetics of galectin-3 in 55 end stage heart failure patients with the need for 
mechanical circulatory support (MCS).  Notably, this study found that fibrosis related 
biomarkers, such as tissue inhibitor of metalloproteinase (TIMP), tenascin C (TNC), OPN, 
BNP and galectin-3 were all increased in patients with terminal heart failure. Interestingly, 
MCS only reduced the loading related biomarker BNP, but none of the other fibrosis related 
biomarkers. Additionally, patients who did not survive on MCS had higher baseline galectin-3 
levels when compared with patients who lived until transplantation [45].  
Then, a larger study by Lok et al. comprising 232 patients with chronic heart failure (New 
York Heart Association function class III or IV) demonstrated that patients with high baseline 
levels of both galectin-3 and NT-proBNP had around 1.5- to 2-fold higher mortality rate 
Figure 2B  [46]. This study demonstrated incremental value of galectin-3 over NT-proBNP 
alone. 
Additionally, a large study of 592 patients with heart failure (Coordinating study 
evaluating outcomes of Advising and Counseling in Heart failure, COACH  trial, [47]), with 
mean follow-up of 18 months supported prognostic value of galectin-3 to predict re-
hospitalization and death after correction for age, gender, BNP, eGFR and diabetes, but not 
after correction for LVEF. A subanalysis revealed that increased plasma galectin-3 levels 
represents a stronger incremental risk in patients with preserved LVEF (HFPEF) compared to 
the patients with reduced LVEF (HFREF) (P<0.001) even when absolute galectin-3 levels did 
not differ between patients with HFPEF and HFREF [47] Figure 2C.  
Furthermore, in the HF-ACTION study where plasma galectin-3 levels were assessed in 
895 subjects with heart failure from a randomized, controlled trial of exercise training in 
patients with chronic heart failure with NYHA class II, III or IV symptoms, galectin-3 was 
associated with NYHA class, lower systolic blood pressure, higher creatinine, higher NT-
proBNP, and lower maximal oxygen consumption. However, this association diminished after 
adjustment for NT-proBNP [48].  
Finally, recent data show that small increases in galectin-3 may confer increased CV risk 
in the general population, in subjects at risk for heart failure development. Briefly, 7968 
subjects were included in this study from the Prevention of Renal and Vascular End-stage 
Disease (PREVEND) cohort (mean age of 50 ± 13 years, median follow-up of approximately 
10 years). Plasma galectin-3 levels correlated very strong with age and sex Figure 2D, and 
weakly with a wide range of risk factors of CV disease, including blood pressure, serum lipids, 
body mass index, renal function and NT-proBNP. After correction for classical CV risk 
factors (smoking, blood pressure, cholesterol and diabetes), increased plasma galectin-3 levels 
independently predicted all-cause mortality in a large community/based cohort [49].  
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Altogether, these available clinical studies have so far confirmed that plasma galectin-3 
levels was significantly up regulated in acutely decompensated heart failure[43, 44, 50, 51], 
chronic heart failure [46-49] and end-stage heart failure with the need for mechanical 
circulatory support (MCS) [52]. Furthermore, clinical results from our group further 
demonstrated the predictive and prognostic value of galectin-3 [46, 47, 49].  A relationship 
between galectin-3 and cardiovascular (CV) risk factors was investigated in the general 
population of PREVEND study, and a strong gender specific interaction was revealed in the 
correlation between galectin-3 and cardiovascular risk factors [49].  Notably, the established 
link between plasma galectin-3 and fibrosis was also established in clinical biomarker studies 
[52] and needs to be explored further in order to develop more efficient strategies to target 
cardiac remodeling in heart failure leading to fibrosis.   
 
CONCLUSION AND MAPPING OF GALECTIN-3 PATHWAYS  
In conclusion, galectin-3 is highly expressed in the fibrotic area of the failing or stressed 
heart [14, 17, 19, 21, 22] and cardiac fibroblasts and macrophages are the main sources of 
galectin-3. Further, galectin-3 was shown to activate the TGF-β/Smad3 pathway [22], while 
 
Figure 4: Working scheme representing the sequence of events following an index event (such as myocardial 
infarction (MI), hypertension, myocarditis and cardiomyopathy) leading to remodeling and non-remodeling heart 
failure. The graph within this graphic is taken from the de Boer et al. [8] and represents the adjusted Cox 
regression curves for quartiles of plasma galectin-3 showing the cumulative risk for the combined end-point, 
death. The back circles with the white numbers represent quartile 1 through 4, respectively. Galectin-3 is 
displayed as a central modulating factor involved in the remodeling process which leads to ongoing damage and 
eventually poor heart failure outcome. Therapeutically, galectin-3 inhibition could favor non-remodeling heart 




macrophages and the inflammatory factor TGF-β demonstrated to elevate galectin-3 
expression. Then, galectin-3 inhibition or deficiency was found to not affect macrophage 
activation and TGF-β expression levels. Therefore, galectin-3 may be considered as an 
independent participant in macrophage and TGF-β/Smad modulation pathway.  
Other experimental animal studies reported that galectin-3 was not only significantly 
associated with myofibroblast induced collagen synthesis and deposition but was also 
markedly correlated with ECM fibrosis markers, such as: α-SMA, COL1A1, COL3A1, TIMP, 
MMP [53] Figure 3(see Chapter 2 Figure 1).  
Lastly, relevant clinical studies identified that plasma galectin-3 is significantly correlated 
with serum extracellular fibrosis turn over biomarkers, like PINP, PIIINP, TIMP, MMP. 
Collectively, galectin-3 may be suggested as “culprit biomarker” involved in pathophysiology 
circle of cardiac remodeling and heart failure. A suggested pathway of galectin-3 is displayed 
in Figure 4 [56]. 
Data from experimental renal damage and cancer suggest to galectin-3 is a feasible target 
for therapy. Our pilot data lend support to the notion that also in heart failure galectin-3 may 
be a target for therapy. More research is warranted herein, specifically, at what stage galectin-
3 comes into play and what the ideal window would be for intervention. Most data show that 
preventative regimen might work, but if fibrosis, once ensued, could be attenuated or reversed 
is also unknown. From a clinical point of view this is of utmost importance.  
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Background - Galectin-3 has been implicated in the development of organ fibrosis. It is 
unknown whether it is a relevant therapeutic target in cardiac remodeling and heart failure 
(HF). 
Methods and Results - Galectin-3 knock-out (Gal3-KO) and wild-type (WT) mice were 
subjected to angiotensin II (AngII) infusion (2.5 µg/kg for 14 days) or transverse aortic 
constriction (TAC) for 28 days to provoke cardiac remodeling. The efficacy of the galectin-3 
inhibitor N-acetyllactosamine (Gal3i) was evaluated in TGR(mREN2)27 (REN2) rats and in 
WT mice with the aim of reversing established cardiac remodeling following TAC. In WT 
mice, AngII and TAC perturbations caused left ventricular (LV) hypertrophy, decreased 
fractional shortening and increased LV end-diastolic pressure and fibrosis (P<0.05 vs. control 
WT). Gal3-KO mice also developed LV hypertrophy but without LV dysfunction and fibrosis 
(P=NS). In REN2 rats, pharmacological inhibition of galectin-3 attenuated LV dysfunction 
and fibrosis. To elucidate the beneficial effects of galectin-3 inhibition on myocardial 
fibrogenesis, cultured fibroblasts were treated with galectin-3 in the absence or presence of 
Gal3i. Inhibition of galectin-3 was associated with a downregulation in collagen production 
(collagen I and III), collagen processing, cleavage, cross-linking and deposition. Similar 
results were observed in REN2 rats. Inhibition of galectin-3 also attenuated the progression of 
cardiac remodeling in a long-term TAC mouse model. 
Conclusions - Genetic disruption and pharmacological inhibition of galectin-3 attenuates 
cardiac fibrosis, LV dysfunction and subsequent HF development. Drugs binding to galectin-3 






















Galectin-3 belongs to the galectin family of mammalian lectins and is characterized by a 
carbohydrate recognition domain (CRD) that has affinity for β-galactosides. Galectin-3 
mediates cell–cell and cell–matrix interactions by binding to lactosamine-containing cell 
surface glycoconjugates via its CRD. There is mounting evidence demonstrating its key role 
in inflammatory and fibrotic processes.1 
In experimental models, galectin-3 was found to be involved in the development of liver 
and kidney fibrosis.2,3 It has also been associated with cardiac fibrosis in TGRmREN2-27 
(REN2) rats with experimental heart failure (HF).4 A continuous intrapericardial infusion of 
low-dose galectin-3 resulted in cardiac fibrosis and left ventricular (LV) dysfunction in both 
failure-prone hypertrophic REN2 and healthy Sprague-Dawley rats.4,5 The upregulation of 
galectin-3 has also been demonstrated in failing human hearts4 and circulating levels are a 
powerful predictor of outcome in both acute and chronic HF. This observation has led to the 
approval of galectin-3 by the Food and Drug Administration as a novel biomarker in HF that 
may help categorize patients in the remodeling and non-remodeling stages of HF.6,7 
Despite evidence suggesting the involvement of galectin-3 in the pathophysiology of HF, 
it remains unknown if it contributes actively to the disease. In the present study, we 
determined if the disruption of the galectin-3 gene, shown to attenuate hepatic and renal 
fibrosis in galectin-3 knock-out (Gal3-KO) mice,2,8 would prevent the development of HF in 
animals with active cardiac remodeling. Furthermore, because the beneficial effects of 
targeted CRD inhibition of galectin-3 have been demonstrated in a model of kidney injury,3 
we also determined the effects of a galectin-3 inhibitor (Gal3i), N-acetyllactosamine (N-Lac), 
which has a high affinity for galectin-3 CRD, in TGR(mREN2)27 (REN2) rats with HF and in 
mice subjected to transverse aortic constriction (TAC). 
 
Methods 
For detailed description of the methods, please refer to the Online Supplemental Data. 
Animals 
Male Gal3-KO mice were generated and bred at the Jackson Laboratory (Bar Harbor, ME, 
USA) as described previously.2,8,9 Age-matched male transgene-negative wild-type (WT) 
littermates were used as controls. Supplemental Figure S1A depicts the generation of Gal3-
KO mice. Male homozygous REN2 (Max Delbrück Center for Molecular Medicine, Berlin 
Buch, Germany) and age-matched male Sprague-Dawley (SD) rats (controls) were used as 
described previously.10-12 All experiments were approved by the Animal Ethical Committee of 
the University of Groningen (the Netherlands) and conducted in accordance with existing 




Six- to 10-week old Gal3-KO and WT mice were subjected to an infusion of angiotensin 
II (AngII) (2.5 µg/Kg/day) for 14 days or LV pressure overload by TAC for 28 days 
(prevention experiment).13 In another series of experiments (reversal experiment), six- to 
eight-week old male C56Bl6/J mice (Harlan, The Netherlands) underwent TAC for 28 days 
and were then treated with N-Lac (5 mg/Kg/day, intraperitoneal (i.p.) injections) three times a 
week for 28 days (starting day 28 until day 56).14 
Rat experiments 
SD and REN2 rats were treated with N-Lac (5 mg/Kg/day, i.p.) three times a week for six 
weeks. 
Other experiments 
Cardiac function was studied with echocardiography and hemodynamic measurement as 
described previously.15,16 Immunohistochemical analyses were performed and collagen 
digestibility was determined.17 Cell cultures of human adult dermal fibroblasts were used to 
study galectin-3-mediated fibrogenesis and the effects of N-Lac. Cardiac and fibroblast gene 
expression was measured using RT-qPCR as described previously.18 The lists of primers are 
presented in Supplemental Tables S1, 2 and 3. 
Statistical analyses 
Results are reported as mean ± standard error of the mean (SEM). Mice were analyzed in 
two separate subgroups comparing genotype differences (WT vs. KO) and model differences 
(control vs. AngII or sham vs. TAC). Subgroup A consisted of WT-control, Gal3-KO-control, 
WT-AngII, Gal3-KO-AngII and subgroup B consisted of WT-sham, Gal3-KO-sham, WT-
TAC and Gal3-KO-TAC. 
Levene’s test was used to test homogeneity of variances within parameters . If there was 
equality of variances, statistical analyses were performed by one-way ANOVA with 
Bonferroni post-hoc  tests (mice group A M=6 tests, mice group B M=6 tests, rats M=3 tests). 
If there was unequality of variances, statistical analyses were performed by Welch’s ANOVA 
with Games-Howell post-hoc test. Cell experiments were analyzed with Kruskall-Wallis test 
(N=3 per group). For the TAC reversal experiment, differences between saline treated mice 
and N-Lac treated mice were analyzed at the eight week time point using an unpaired t-test 
(N=7-9). Baseline TAC reversal is depicted as a dotted line. In all figures, only relevant 
comparisons are shown by the symbols for reasons of clarity. All P-values are two-tailed and a 
value less than 0.05 was considered significant. All analyses were performed using SPSS 
version 20.0 software (SPSS, Chicago, IL, USA). 
 
Results 



































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 1  Hemodynamic data in mice and rats at sacrifice. (a) Outline of the experimental protocol of the 
prevention studies in mice and rats. (b) Expression of atrial natriuretic peptide (ANP) mRNA in mouse hearts. (c) 
Fractional shortening in mouse hearts assessed with echocardiography. (d) Left ventricular end diastolic pressure 
(LVEDP) in mouse hearts. (e) Isovolumetric relaxation constant Tau in mouse hearts. (f) dPdtmin corrected for 
peak systolic pressure in mouse hearts. (g) Expression of ANP mRNA in rat hearts. (h) Fractional shortening in 
rat hearts assessed with echocardiography. (i) Change in fractional shortening in rat hearts assessed with 
echocardiography at baseline and prior to sacrifice. (j) LVEDP in rat hearts. (k) Tau in rat hearts. AngII: 
angiotensin II; TAC: transverse aortic constriction; Wk: week; Gal3i: galectin-3 inhibitor (N-Lac: N-
acetyllactosamine); con: control. N=5-12 per group. * P<0.05 vs. WT-con, † P<0.05 vs. Gal3-KO-con, ‡ P<0.05 
vs. WT-AngII, § P<0.05 vs. WT-sham, # P<0.05 vs. Gal3-KO-sham, ** P<0.05 vs. WT-TAC, †† P<0.05 SD-
con vs. REN2-con, ‡‡ P<0.05 REN2-con vs. REN2-Gal3i, §§ P<0.05 SD-con vs. REN2-Gal3i  , ## P<0.05 vs. 
all other groups at sacrifice. 
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The intervention and treatment schemes of the WT and Gal3-KO mice are presented in 
Figure 1a and the baseline characteristics and hemodynamic data at sacrifice are presented in 
Table 1. When compared with control or sham, LV galectin-3 expression was increased 
almost 2-fold in WT mice treated with AngII or TAC while galectin-3 expression was absent 
in Gal3-KO mice (mRNA and protein, Supplemental Figure S1 b-d). In the WT mice, both  
interventions caused LV hypertrophy as evidenced by the increases in LV weight (normalized 
to tibia length, Table 1), wall thicknesses (Table 1) and LV atrial natriuretic peptide (ANP) 
expression (Figure 1b) along with a decrease in contractile function (fractional shortening, FS, 
Figure 1c). Hemodynamic measurements revealed LV relaxation impairment in the WT 
groups (Figure 1d-f) with increases in LVEDP and Tau (an isovolumetric relaxation constant 
measured according to the Glantz method) along with decreases in dPdtmin (corrected for 
peak systolic pressure). 
As shown in Table 1, both Gal3-KO and WT mice subjected to AngII infusion or TAC 
had a similar degree of LV hypertrophy. However, and irrespective of the perturbation, Gal3-
KO mice had preserved FS (Figure 1c). Hemodynamic measurements revealed that Gal3-KO 
mice were protected against LV relaxation impairment following AngII infusion or TAC 
(Figures 1d-f), which did not result in changes in LVEDP and Tau (P=NS vs. respective 
controls). The only exception was the corrected dPdtmin which was significantly decreased in 
the Gal3-KO-AngII group. 
 
Inhibition of galectin-3 with N-acetyllactosamine prevents left ventricular dysfunction in 
failure-prone REN2 rats  
The intervention and treatment schemes of the SD and REN2 rats are presented in Figure 
1a. Table 2 shows the baseline characteristics and hemodynamic data at sacrifice. As expected, 
LV weight (adjusted for tibia length) was significantly increased in the untreated REN2 rats. 
Treatment with N-Lac did not prevent the development of LV hypertrophy or decrease LV 
ANP levels (Table 2, Figure 1g). Fractional shortening (FS) progressively declined in the 
untreated REN2 rats (Figure 1i) but was preserved in the Gal3i-treated rats (Figure 1h). 
Hemodynamic measurements revealed an increased LVEDP in the untreated REN2 rats as 
compared with the SD rats (Figure 1j) as well as Tau (Figure 1k), associated with increased 
lung weights (Table 2), all suggestive of developing HF. Treatment with Gal3i reduced 
LVEDP in REN2, and lung weigh, but not Tau. Finally, accelerated cardiac remodeling in 
untreated REN2 rats was associated with poorer survival than Gal3i-treated REN2 rats 
(Supplemental Figure S2). 
 
Galectin-3 disruption or inhibition attenuates the formation of fibrosis in the heart 
To determine if galectin-3 is actively involved in the formation of fibrosis, we analyzed 
the presence of myocardial fibrosis. Figures 2a and 2b show representative pictures of fibrotic 
tissue and the fibrosis score in mouse hearts. The hearts of control and sham-operated WT 





































































































































































































































































































































































































































































































































































































































































Figure 2  Fibrosis in mouse and rat hearts. (a) Typical examples of fibrosis staining with Masson’s trichrome 
staining in mouse hearts. (b) Percentage of fibrosis in mouse hearts. (c) Typical examples of fibrosis staining in 
rat hearts. (d) Percentage of fibrosis in rat hearts. (e) Collagen cross-linking represented as collagen digestibility 
in rat hearts. (f) Level of PINP measured in rat blood plasma. Con: control; AngII: angiotensin II; TAC: 
transverse aortic constriction; Gal3i: galectin-3 inhibitor. N=5-12 per group. * P<0.05 vs. WT-con, ‡ P<0.05 vs. 
WT-AngII, § P<0.05 vs. WT-sham, ** P<0.05 vs. WT-TAC, †† P<0.05 SD-con vs. REN2-con, ‡‡ P<0.05 
REN2-con vs. REN2-Gal3i, §§ P<0.05 SD-con vs. REN2-Gal3i 
 
in the WT-AngII and WT-TAC mice (Figure 2b). However, neither AngII infusion nor TAC 
resulted in increased fibrosis in Gal3-KO animals. Similar results were also observed in rat 
hearts. Compared with SD rats, REN2 rats exhibited a high percentage of fibrotic tissue and 
treatment with Gal3i significantly reduced the percentage of fibrosis in the REN2 rats (Figure 
2c, 2d). 
We evaluated collagen digestibility (% collagen released by proteolytic enzymes) as a 
measure of the extent of collagen cross-linking. In our assay, the higher the numbers of cross-
links, the lower the amount of released collagen.19,20 Compared with SD rats, collagen 
digestibility was significantly reduced in the hearts of REN2 rats (Figure 2e). As collagen  
fibers in fibrotic lesions display a higher level of pyridinoline cross-links making them more 
resistant to the enzymatic action of proteinases,20 our results indicate the presence of more 
cross-linked collagen in the hearts from untreated REN2 rats (Figure 2e). Treatment of REN2 
rats with Gal3i resulted in a collagen digestibility similar to that of SD rats (figure 2e). 
We also measured the plasma levels of PINP, a marker of collagen cleavage, with an 
ELISA assay. In REN2 rats, PINP was significantly increased compared with SD rats and 
inhibition of galectin-3 resulted in a significant reduction of PINP concentration (Figure 2f).  
Collectively, these results suggest that Gal3i can reduce pathological fibrosis through a 




Figure 3  Histological analysis of rat hearts. (a) Typical examples of Gomori staining for cardiomyocyte size, α-
SMA staining for myofibroblasts, CD68 staining for macrophages and PCNA staining for proliferating cells. (b) 
Quantification of cardiomyocyte size. (c) Quantification of α-SMA staining. (d) Quantification of macrophages 
per mm2. (e) Quantification of proliferating cells per mm2. Con: control; Gal3i: galectin-3 inhibitor. N=5-8 per 
group. †† P<0.05 SD-con vs. REN2-con, ‡‡ P<0.05 REN2-con vs. REN2-Gal3i, §§ P<0.05 SD-con vs. REN2-
Gal3i 
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Galectin-3 inhibition reduces the number of α-SMA positive cells in the heart 
Figure 3 shows typical examples of Gomori, α-SMA, CD68 (a macrophage marker) and 
PCNA staining in rat hearts with their respective quantification. Cardiomyocyte size and α-
SMA expression were significantly increased in REN2 rats. Treatment with Gal3i did not 
decrease cardiomyocyte size (Figure 3a, 3b) but it normalized α-SMA expression indicating a 
lower number of myofibroblasts in these groups (Figure 3a, 3c). The number of macrophages 
was also increased in both REN2 groups (Figure 3a, 3d), as was the number of proliferating 
cells, although this was only significant in the untreated REN2 group (Figure 3a, 3e). 
Immunohistochemical analysis revealed that galectin-3 immunoreactivity was predominantly 
observed in the interstitial space, but not in cardiomyocytes (Supplemental figure S3). In an 
effort to determine the localization of cardiac galectin-3 and its source, we conducted further 
studies. We observed that galectin-3 co-localized with macrophages (Supplemental figure S4 
a-d) and at sites of collagen deposition (Supplemental figure S4, e-h). Furthermore, galectin-3 
 
 
Figure 4  Effects of galectin-3 and Gal3i on human dermal fibroblasts (HDF) (a) Typical examples of HDF 
appearance with or without treatment. (b) Confirmation of fibroblast phenotype by vimentin staining. (c) Most 
significantly regulated genes from the Low Density Array. (d-j) confirmation of differential expression of genes 
identified in the low density array by RT-qPCR: (d) HSP47, (e) COL1A1, (f) COL1A2, (g) COL3A1, (h) P4HB, 
(i) PCOLCE, (j) LOXL2. (k) Amount of collagen 3 (COL3) in the tissue culture medium measured with ELISA 




protein expression was highest in macrophages. Galectin-3 protein expression was also clearly 
detectable in fibroblast, but was not detectable in cardiomyocytes (Supplemental figure S5). 
 
Galectin-3 inhibition prevents galectin-3-mediated effects in human dermal fibroblasts 
Stimulation of human dermal fibroblasts with recombinant galectin-3, with or without 
Gal3i, did not lead to visible differences in fibroblast appearance (Figure 4a). Fibroblast 
phenotype was confirmed by staining for the mesenchymal marker vimentin (Figure 4b). 
Since our preliminary results demonstrated that the mRNA level of COL1A1 in the presence 
of galectin-3 peaked 72 hours post-stimulation (data not shown), the expression of various 
fibrillar collagens and proteins involved in their processing was measured at the 72h time  
 
Figure 5  Changes in gene expression of fibrotic genes in rat hearts. (a-h) mRNA expression in rat hearts: (a) 
Galectin-3, (b) Hsp47, (c) Col1a1, (d) Col1a2, (e) Col3a1, (f) P4hb, (g) Pcolce, (h) Loxl2,  N=5-12 per group. (i) 
Western Blots for galectin-3, Hsp47 and GAPDH. (j) Galectin-3 protein expression measured with Western Blot. 
(k) Hsp47 protein expression measured with Western Blot. N=4 per group. Gal3i: galectin-3 inhibitor. †† P<0.05 
SD-con vs. REN2-con, ‡‡ P<0.05 REN2-con vs. REN2-Gal3i, §§ P<0.05 SD-con vs. REN2-Gal3i. 
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point with a low density array (overview in Supplemental Table S4; results are shown in 
Figure 4). The expression of COL1A1, COL1A2, COL3A1 and the collagen-modifying 
proteins encoded by P4HB, HSP47, PCOLCE and LOXL2 were all upregulated by galectin-3 
(Figure 4, d-j) and inhibited by Gal3i co-treatment. The modulation of COL3A1 transcript 
expression by galectin-3 and Gal3i was also reflected in collagen type III levels in the culture 
medium measured with an ELISA (Figure 4 k). 
 
Genes involved in myocardial fibrogenesis 
The expression of the above-mentioned collagens and fibrosis-associated proteins was 
subsequently analyzed in the LV tissue of SD and REN2 rats by RT-qPCR (figure 5, a-h; 
primers are listed in Supplemental Table S2). These results confirm our in vitro observations 
with human fibroblasts and show that Gal3i reduces the expression of pro-fibrotic genes also 
 
Figure 6  Gal3i inhibits progression of cardiac remodeling in mice. (a) Outline of the experimental protocol. (b) 
Left ventricular (LV) weight corrected for tibia length (TL) at sacrifice. (c) Fractional shortening assessed with 
echocardiography at sacrifice. (d) Left ventricular end diastolic pressure (LVEDP). (e) Atrial natriuretic peptide 
(ANP) mRNA expression in mouse hearts. (f) Amount of fibrosis in mouse hearts. (g) Typical examples of 
Masson’s trichome staining in mouse hearts. TAC: transverse aortic constriction; Wk(s): week(s); Gal3i: 
galectin-3 inhibitor; sal: saline, NS: no-significant. N=7-9 per group. Differences between groups were compared 
at the eight weeks timepoint (t-test), baseline four weeks is depicted as a dotted line. 
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in vivo. We also measured the LV protein expression of galectin-3 and Hsp47 in lysates from 
SD and REN2 rat hearts (figure 5, i-k). Galectin-3 and Hsp47 protein levels were increased in 
untreated REN2 rats. Treatment with the Gal3i resulted in decreased Hsp47 (figure 5k) but not 
galectin-3 (figure 5j) protein levels, which reflects the changes in mRNA expression (figure 
5a-b). Finally, we analyzed the transcript levels of matrix metalloproteinases (MMP) 2 and 9 
and tissue inhibitors of matrix proteases (TIMP) 1 and 2 in LV tissue of SD and REN2 rats. 
Mmp-9, Timp-1, and Timp-2 levels were increased in untreated REN2 rats and reduced by 
treatment with a Gal3i (Supplemental figure S6). 
 
Galectin-3 inhibition prevents further progression of established left ventricular 
remodeling 
We provoked LV remodeling with TAC surgery followed by an observational period of 
28 days without intervention (Figure 6a). We then treated the mice with N-Lac or saline for 
another 28 days. At the end of the follow-up period, no increase in LV weight (figure 6b) was 
observed. Treatment with Gal3i for 28 days had no effect on LV weight, compared with the 
LV weights after the 28-day observational period (Figure 6b). However, a gradual progression 
of LV remodeling was observed in the untreated mice as evidence by the further decline in FS 
(Figure 6c) and by an increase in ANP levels (Figure 6e) and fibrosis (Figure 6f, g). In the 
Gal3i-treated mice, LVEDP was lower compared to untreated mice (Figure 6d). 
 
Discussion 
The current study provides several lines of evidence that galectin-3 is an active 
contributor in the development of cardiac remodeling, myocardial fibrogenesis and HF. We 
have demonstrated that inhibition of galectin-3 function by genetic disruption or 
pharmacological intervention halts the progression of cardiac remodeling, attenuates 
myocardial fibrogenesis and preserves LV function. These beneficial effects can be explained, 
at least in part, by the lower number of myofibroblasts in combination with diminished 
collagen synthesis, processing and cross-linking. Collectively, our results suggest that 
galectin-3 may be an attractive target for the prevention and treatment of HF. 
 
Disruption of galectin-3 attenuates cardiac remodeling and preserves cardiac function 
To explore the hypothesis that galectin-3-targeted interventions may protect against 
progressive cardiac remodeling and dysfunction, two experimental approaches were used in 
well-established mouse and rat models of cardiac remodeling: 1) complete genetic disruption 
of galectin-3 and 2) pharmacological inhibition with an agent that specifically binds to the 
CRD of galectin-3. Both the genetic disruption and pharmacological inhibition of galectin-3 
resulted in considerable attenuation of cardiac remodeling and, specifically, to an almost it is 
complete inhibition of cardiac fibrosis. Functionally, the inhibition of galectin-3 improved 
diastolic dysfunction to a large extent (less increase in end-diastolic LV pressure and 
improved LV relaxation) in spite of the presence of significant LV hypertrophy. In this respect, 
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it is noteworthy that elevated levels of circulating galectin-3 have been shown to be strong 
predictors of poor outcome in patients with “diastolic HF” or HF with preserved LV ejection 
fraction.21 
Although the animals in our experimental models were mainly characterized by impaired 
diastolic function, mild (AngII, TAC-prevention) to moderate (REN2, TAC-reversal) systolic 
dysfunction also developed over time. Inhibition of galectin-3 preserved systolic function, a 
finding that was above all apparent in the reversal experiment where treatment was started 
after four weeks of TAC. In the untreated mice, mild systolic dysfunction was present after 
four weeks (figure 6c) and progressed over another four weeks of follow-up to overt systolic 
dysfunction (figure 6c). However, when mice were treated with the galectin-3 inhibitor, 
progression of systolic dysfunction was attenuated. These results suggest that galectin-3 
inhibition might afford functional protection against developing and progressive cardiac 
remodeling. 
Additional evidence of the important role of galectin-3 in cardiac remodeling was 
obtained by treating REN2 rats with N-acetyllactosamine, an established inhibitor that binds 
to the galectin-3 CRD.14,22,23 The homozygous REN2 rat model is a well described model of 
rapidly progressive cardiac remodeling driven by renin overexpression with changes typical 
for HF such as increased sympathetic tone, LV hypertrophy, myocardial fibrosis and stress-
related pathways.4,10,12 Results of our study show that the typical course of HF development, 
characterized by impaired LV relaxation and fast progression (within weeks) to overt HF, was 
attenuated by galectin-3 inhibition. It remains to be determined if galectin-3 inhibition is 
equally effective in other multifactorial models of HF such as the spontaneous hypertensive 
rat or post-myocardial infarction HF, as a single treatment or in addition to established HF 
therapy. 
 
Mechanisms underlying the cardioprotective effects of galectin-3 inhibition 
Fibrosis is accepted as one of the main determinants of cardiac remodeling. Cessation of 
the fibrotic process is one of the key targets to reverse cardiac remodeling and improve 
prognosis. Fibroblasts, together with myofibroblasts and macrophages, have been identified as 
key cells in the fibrotic process.24-26 The striking observation that myocardial fibrogenesis was 
strongly inhibited when galectin-3 was genetically disrupted or pharmacologically inhibited 
lead us to investigate the effect of galectin-3 on the fibrotic process. First, we showed in 
REN2 rats that pharmacological inhibition of galectin-3 lead to a lower number of 
myofibroblasts along with less collagen synthesis (lower PINP plasma levels) and deposition. 
We substantiated these changes by showing that the stiffness of the fibrotic depositions 
was also altered. In the collagen digestibility assay, the collagenase digested more collagens in 
Gal3i-treated REN2 rats (Figure 2e) indicating less cross-linked fibrotic tissue. Studies on for 
fibrogenesis-related gene profiles in fibroblasts treated with recombinant galectin-3 revealed 
changes in several genes relevant to the extracellular matrix processing. In vitro incubation of 
human dermal fibroblasts with galectin-3 resulted in significant upregulation of genes coding 
ŚĂƉƚĞƌϰ
ϳϬ 
for various fibrillar collagens (COL1A1, COL1A2 and COL3A1) and genes involved in the 
modification of (pro)collagens including prolyl-4-hydroxylase (P4HB), heat shock protein 47 
(HSP47 or SERPINH1), the procollagen C-endopeptidase enhancer (PCOLCE) and the lysyl 
oxidases (LOXL2). Inhibition of P4Hs has been shown to inhibit fibrosis and preserve cardiac 
function in HF.27-29 Also, the antisense HSP47 was associated with less myocardial fibrosis 
protecting hearts from post myocardial infarction remodeling.30 Importantly, treatment with 
N-acetyllactosamine downregulated the expression of all these genes to baseline levels. These 
results suggest that galectin-3 may affect several steps involved in fibrogenesis,  from 
enhanced synthesis of procollagen to the regulation of various enzymes involved in the 
processing of procollagen into mature intra and extracellular collagen. The activation of these 
pathways is attenuated by galectin-3 inhibition (figure 7). 
 
 
Figure 7  Schematic representation of myocardial fibrogenesis and the effects of galectin-3  and galectin 3 
inhibition. Upon cardiac stressors (in our study: AngII, TAC, REN2, and rh-Galectin-3 treatment), (cardiac) 
fibroblasts differentiate into myofibroblasts and collagen production increases. Intracellularly, procollagen chains 
are processed by various gene products, and then secreted into the interstitium. Here, the procollagens are 
cleaved to become collagens and further processed, resulting in aggregation, maturation, and cross-linking. 
Finally, the deposited cross-linked collagens in the myocardium add to myocardial fibrosis and dysfunction. 
Along this process, galectin-3 exerts effects on genes involved in the various steps of fibrogenesis, and galectin-3 
inhibition with N-Lac inhibits these various steps.  
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As the effect of galectin-3 on fibroblasts provides an explanation as to why in vivo 
galectin-3 inhibition results in the cessation of the fibrotic process, we validated these findings 
in REN2 rats. The cardiac expression of Col1a1, Col1a2, Col3a1, P4hb, Hsp47 (Serpinh1), 
Pcolce and Loxl2 genes was upregulated and treatment with N-acetyllactosamine normalized 
their expression to levels similar to those of control SD rats. These observations were further 
substantiated by showing, both in vitro and in vivo, decreased collagen levels in culture 
medium (fibroblasts) and plasma (REN2 rats), increased collagen digestibility (figure 2e), 
regulation of MMPs and TIMPs (Supplemental figure S6) and decreased myocardial fibrosis 
upon Gal3i treatment (figure 2d). 
Overall, our results point towards a pivotal role of galectin-3 in cardiac fibrosis. The 
general effect of galectin-3 on cardiac remodeling, due to myocardial fibrogenesis, appeared 
to be similar between mice and rats. Furthermore, the same fibrogenic effects of galectin-3 
(and its inhibition by N-acetyllactosamine) were observed in primary human fibroblasts and in 
REN2 rat hearts. 
 
Other observations 
LV weight was increased in Gal3-KO mice and in REN2 rat treated with N-
acetyllactosamine. The mechanism(s) underlying this observation has not been elucidated as 
we were not able to detect appreciable protein expression of galectin-3 in cardiomyocytes in 
our preliminary experiments. It has also been reported that galectin-3 is mainly produced by 
macrophages homing to sites of injury.4,8 We confirmed the influx of macrophages and the co-
localization of galectin-3 with macrophages in our REN2 models (Supplemental figures S4 
and S5). However, anti-galectin-3 treatment did not reduce the number of macrophages 
(figure 3d). It has been suggested that the activation of macrophages is more pivotal than the 
number of macrophages in the development of cardiac remodeling. Usher and colleagues31 
described mice with a deletion of the mineralocorticoid receptor in macrophages and showed 
they were protected against cardiac remodeling. Our findings do not exclude a role for 
macrophages in galectin-3-mediated HF but, from the data presented herein, we conclude that 
Gal3i exerts its effects primarily via binding to the CRD of galectin-3, that prevents a pro-




Clinical proof for a role of galectin-3 in HF comes from several studies reporting the 
value of galectin-3 as a biomarker in HF.6,21,32-34 In the general population, it has been recently 
observed that sustained elevation in galectin-3 levels may contribute to increased 
cardiovascular risk, all cause mortality (PREVEND cohort)35 and new onset HF (Dr. J. Ho, 
Framingham Heart Study, unpublished data, 2012). Our data lend further support to the role of 
galectin-3 in cardiac remodeling as well as its potential role as a target for therapy. Future 
studies are being designed to establish the role of galectin-3 inhibitory compounds in HF of 
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different etiology or on top of established HF therapy. Since high galectin-3 levels may 
predispose for the development of HF, therapies targeted against galectin-3 may afford 
protection. Interestingly, although speculative, high intake of dietary cereals rich in pectins 
that inhibit galectin-3 has been associated with lower risk for new onset HF.36 
 
Limitations 
We studied only male animals and, given the established differences in cardiac 
remodeling between sexes, our results cannot be extrapolated to female animals. Furthermore, 
results on cardiac contractility and relaxation should be interpreted with caution as no load-
independent measures of LV function were reported (EES, EED, PRSW, etc). Because we 
only tested one dose of N-acetyllactosamine, dose-finding studies are warranted. Finally, not 
all fibrotic genes responded to the same extent in our different models. This might be 
attributed to the differences in etiology, model severity or to differences between mice and 
rats. Nevertheless, and despite some gene-specific differences, the overall response to 
galectin-3 interference (inhibition and knock-out) was similar. 
 
Conclusions 
Genetic disruption of galectin-3 and pharmacological inhibition of galectin-3 attenuated 
the progression of cardiac remodeling in murine and rat models of HF. Inhibition of galectin-3 
largely preserved systolic and diastolic function via the inhibition of myocardial fibrosis and 
decreased collagen production, processing and cross-linking. Future, more in depth, 
mechanistic studies would be needed to address the precise role of galectin-3 in HF 
development. At later stages of remodeling, galectin-3 inhibition prevented further HF 
progression. Taken together, our results strongly suggest a causal role of galectin-3 in the 
development of cardiac remodeling and HF and we postulate that galectin-3-targeted therapy 
may potentially be a useful addendum in the treatment of HF.  
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We studied six- to ten-week old male mice deficient for the gene encoding galectin-3 
(galectin-3 knock-out mice (Gal3-KO)). The Gal3-KO homozygous mice carrying a targeted 
mutation in galectin-3 (a lectin, galactose binding soluble 3 or Lgals3) have been generated 
and are bred at Jackson Laboratory (Bar Harbor, ME, USA) and shipped to Groningen, The 
Netherlands. A targeting vector containing neomycin resistance and herpes simplex virus 
thymidine kinase genes was used to disrupt 3.7kb of sequence that includes exons 2, 3 and 4. 
The construct was electroporated into WW6 embryonic stem (ES) cells (derived from 129/Sv, 
C57BL/6 and SJL mixed background mice). Correctly targeted ES cells were injected into 
outbred MF-1 blastocysts. The resulting chimeric male animals were crossed with 129 female 
mice and the mutant strain was backcrossed with C57BL/6 for five generations. For an 
overview of the generation of the Gal3-KO mice, see Supplemental Figure S1. Other 
researchers have generated Gal3-KO mice as well.1-3 Transgene-negative male wild-type (WT) 
served as controls. For the reversal experiment, we used six- to eight-week old male C56Bl6/J 
mice (Harlan, The Netherlands). 
We also studied six-week old, male, homozygous TGR(mREN2)27 rats (REN2). These 
rats overexpress the mouse renin-2 gene (ren-2d) and have a phenotype of severe hypertension 
and left ventricular (LV) hypertrophy which culminates into heart failure (HF) and low blood 
pressure over the course of 12-16 weeks.4-7 The rats were bred at the Max Delbrück Center for 
Molecular Medicine (Berlin Buch, Germany). Since Sprague Dawley (SD) rats represent the 
appropriate control strain for REN2 rats, age-matched male SD rats were used as controls 
(Harlan, The Netherlands).6 
Animals were housed under standard condition. All animal studies were approved by the 
Animal Ethical Committee of the University of Groningen, The Netherlands, and conducted in 
accordance with existing guidelines for the care and use of laboratory animals.  
 
Prevention study - mouse models 
We induced cardiac remodeling by two interventions. First, cardiac remodeling was 
provoked by subcutaneous administration of angiotensin II (AngII) via osmotic minipumps for 
14 days. Second, we induced pressure overload and cardiac remodeling by transverse aortic 
constriction (TAC) for 28 days. The control group received saline infusion via osmotic 
minipumps for 14 days. In total, six groups were studied: WT-con (control, N=10), Gal3-KO-
con (N=10), WT-AngII (N=12), Gal3-KO-AngII (N=10), WT-TAC (N=12) and Gal3-KO-
TAC (N=14). 
AngII (Bachem AG, Bubendorf, Switzerland) was dissolved in 0.9% NaCl and injected 
into osmotic minipumps (Alzet 2004, Durect Corporation, Cupertino, CA, USA). The dose 
delivered by the osmotic minipumps was 2.5 µg/Kg/day. The minipumps were inserted 
subcutaneously on the back of the mice.  
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The TAC is a well established model.8 In brief, mice were anesthetized with oxygen and 
isoflurane (2%), intubated and ventilated. The thoracic cavity was opened between the second 
and the third intercostal cavity. Then, a blunted needle (27G) was placed on the aortic arch 
between both carotid arteries and, with an 8-0 nylon suture, the aorta was tied onto the needle. 
Immediately after, the needle was removed creating a reproducible stenosis of the aorta of 
about 50%. Sham-operated mice served as controls. Mice were sacrificed after 28 days. 
 
Reversal study - mouse model 
The TAC model was used as described above. Mice were left untreated for 28 days. After 
28 days, one third of all animals were sacrificed. The remainder were given intraperitoneal 
injections of the galectin-3 inhibitor (Gal3i) N-acetyllactosamine (N-Lac) (Sigma-Aldrich, 
Zwijndrecht, The Netherlands) that targets the carbohydrate recognition domain (CRD) of 
galectin-3 at a final dose of 5 mg/Kg/day three times per week. N-Lac has been shown to 
effectively bind galectin-3.9 
The treatment period lasted another 28 days and the total study duration was 56 days 
(eight weeks). Control mice were injected with saline. In total, three groups were studied: 
WT-TAC-control (N=9), WT-TAC-saline (N=9) and WT-TAC-Gal3i (N=9). 
 
Rat model 
To study the effect of galectin-3 binding protein on cardiac remodeling, we allocated SD 
and REN2 rats to different treatment regimens. REN2 rats were treated with N-Lac at a final 
dose of 5 mg/Kg/day injected intraperitoneally three times per week. SD rats were used as 
controls for all groups. Rats were sacrificed at week seven of the experimental protocol (when 
aged ~13 weeks). In total, four groups were studied: SD-con (control, N=12), REN2-con 
(N=18), SD-Gal3i (N=8) and REN2-Gal3i (N=10). Treatment with Gal3i did not exert any 
effects in control SD rats and, therefore, the results shown are limited to the REN2 groups. 
 
Echocardiography 
Cardiac function was assessed by echocardiography at baseline and prior to sacrifice with 
Vivid 7 (GE Healthcare, Chalfont St Giles, UK) equipped with a 10-MHz (rats) and a 13-
MHz (mice) phase array linear transducer), as described previously.10 The echocardiographic 
measurements were performed under general anesthesia with 2% isoflurane. Both 2-
dimensional (2D) images in parasternal long-axis and short-axis view and 2-D guided M-
mode tracing were obtained. Parasternal long-axis (PLAX) views were obtained in order to 
ensure that the mitral and aortic valves and the apex were visualized. Left ventricular outflow 
tract (LVOT) diameter was measured in PLAX. Short-axis views were recorded at the level of 
mid-papillary muscles. A total of three loops was recorded and used for calculations. LV end-
systolic diameter (LVESD) and LV end-diastolic diameter (LVEDD) were measured from M-
mode tracings. LV fractional shortening was calculated as (LVEDD − LVESD)/LVEDD × 
100%. Cardiac output was calculated by echo Doppler measurements over the aortic valve 
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(pulsed wave doppler) using the LVOT diameter. To monitor the development of cardiac 
hypertrophy in both mice and rats, echocardiography was performed at baseline and prior to 
sacrifice.  
 
Measurement of hemodynamic function  
Hemodynamic function was assessed invasively as described previously11 by introducing 
a 0.8-French (for mice) and a 1.4 French (for rats) microtip pressure-volume transducer 
(Millar Instr. Inc., Houston, TX, USA) via the right carotid artery into the aorta. A three 
minute period was allowed for stabilization and then systolic and diastolic blood pressure and 
heart rate (HR) were recorded in the aorta (average of 20 heart cycles). The catheter was then 
advanced into the LV. Peak systolic pressure, LV end diastolic pressure (LVEDP), maximal 
indices of LV contraction and relaxation (dPdtmax and dPdtmin) as well as the relaxation 
constant Tau were measured. dPdtmax and dPdtmin were corrected for peak systolic pressure 
to correct for differences in afterload, as described previously.4 
 
Tissue procurement 
After measuring hemodynamics, blood was drawn (PINP assay) and the hearts were 
rapidly excised and weighed. Myocardial tissue was dissected transversally and processed for 
immunohistochemistry or snap frozen for molecular analysis. 
 
Immunohistochemistry  
Hearts were isolated and fixed with buffered 3.7% formalin for 24 hours. Thereafter, 
tissue sections were dehydrated and embedded in paraffin. Another slice was embedded in 
tissue-tec, placed on a carton disk put on a petri-dish and immediately, but slowly, frozen 
above liquid nitrogen. For immunohistochemistry, 3 µm-thick sections were cut on a 
microtome and mounted on slides. Hearts were cut at the mid-papillary level.  
To measure fibrosis, Masson’s trichrome staining was performed on paraffin sections for 
all experimental animals. Whole stained sections were scanned (Nanozoomer 2.0-HT, 
Hamamatsu, Japan) and fibrosis score for the entire section was calculated at 20x 
magnification for mice and 10x magnification for rats (ScanScope, Aperio Technologies, 
Vista, CA, USA). To measure cardiomyocyte size, deparaffinized sections were stained with 
Gomori's silver staining.12 Cardiomyocyte size was measured as the cross-sectional area of 
transversally cut cardiomyocytes at 40x magnification for rats. Myofibroblasts were stained 
with a monoclonal mouse anti-human smooth muscle actin (SMA) antibody (#M0851, DAKO, 
Heverlee, Belgium). SMA in the entire section was calculated at 10x magnification by the 
SanScope software for rats. To measure the number of macrophages, macrophages were 
stained with a mouse anti-rat CD68 (ED1) antibody (#MCA341R, AbD Serotec, Oxford, UK) 
for rats. The number of macrophages was calculated for the entire section using the SanScope 
software at 40x magnification for rats. Proliferating cells were stained with a mouse 
monoclonal anti-PCNA antibody [PC10]-proliferation marker (#ab29, Abcam, Cambridge, 
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UK). The number of proliferating cells in the entire section was calculated by the SanScope 
software at 40x magnification for rats. 
To stain galectin-3 in cardiac tissue, an anti-galectin-3 monoclonal antibody (Thermo 
Fisher Scientific, Landsmeer, The Netherlands) was used. Briefly, paraffin sections were 
dewaxed and subjected to an antigen retrieval procedure by incubating overnight at 80°C in 
0.1M Tris/HCl, pH 9.0. After three washes with TBS, endogenous peroxidase was blocked 
and sections were incubated with the primary antibody (anti-galectin-3 antibody, 1:100) in 1% 
BSA/PBS for 1 hour at room temperature. The sections were then incubated with a secondary 
antibody (polyclonal rabbit anti-mouse IgG/HRP, 1:100) diluted in 1% BSA/PBS buffer for 
two hours. The slides were first stained with 3-animo-9-ethylcarbazole and counterstained 
with hematoxillin. For typical examples of galectin-3 staining in cardiac tissue, see 
supplemental results (Supplemental Figures S3 and S4). 
 
Enzyme-linked immunosorbent assay (ELISA) 
Procollagen type I N-terminal propeptide (PINP), a marker of collagen metabolism, was 
analyzed in plasma using a commercial Enzyme Linked Immunosorbent Assay according to 
the manufacturer’s instructions (rat procollagen I N-terminal propeptide ELISA kit 
#E90957Ra, Uscn Life Science Inc, Wuhan, China). Human collagen type III (Human 
Collagen Type III (Col III) ELISA Kit, Cat No. Hu9614, TSZ ELISA, Framingham, USA) was 
analyzed in human dermal fibroblast supernatant (medium). 
 
Collagen cross-linking assay 
Collagen digestibility was measured following the digestion of tissue samples (for 6 hours 
at 37° C) with Clostridium histolyticum collagenase (Sigma) at a final concentration of 5 µg 
enzyme/mg tissue in a 50 mM Tris buffer containing 5 mM CaCl2 , 0.15 M NaCl, 1 µM 
ZnCl2, 0.02% (w/v) NaN3 and 0.01% (v/v) Brij 35. After incubation, the supernatant and 
remaining tissue were separated and hydrolyzed in 6 M HCl at 110°C for 20-24 hours. The 
relative amount of collagen in the supernatant and remaining tissue was estimated by 
measuring the amount of hydroxyproline in the hydrolysates of both the supernatant and the 
remaining tissue.13 
 
Quantitative real-time PCR 
cDNA synthesis was performed with 0.5 µg total RNA using a specific cDNA synthesis 
kit according to the manufacturer’s protocol (Quantitect Rev. Transcriptase kit, Qiagen, Venlo, 
The Netherlands), as described previously.10,14,15 Quantitative real-time PCR (RT-qPCR) was 
performed using SYBR Green mix according to the manufacturer’s protocol (Absolute SYBR 
Green ROX mix, Thermo Scientific, Breda, The Netherlands) on C1000 Thermal Cycler 
CFX384 Real-Time PCR Detection System (Bio-Rad Laboratories, Veenendaal, The 
Netherlands). All targets were evaluated under the same experimental conditions (95°C for 15 
minutes, then 36 cycles at 95° C for 15 seconds and 60°C for 30 seconds). Samples were 
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analyzed by quantification software (Bio-Rad CFX Manager 1.6). mRNA levels were 
expressed in relative units based on a standard curve obtained with serial dilutions of a 
calibrator cDNA mixture. To normalize expression data, reference genes were used. 
Reference genes were chosen with little sample-to-sample variability (GAPDH and 36B4). 
See Supplemental Tables S1, S2, and S3 for a list of primers used. 
 
Western blotting 
Rat hearts were homogenized in ice-cold RIPA (50 mM Tris pH 8.0, 1% nonidet P40, 
0.5% deoxycholate, 0.1% SDS, 150 mM NaCl) containing phosphatase inhibitor cocktail 1 
(Sigma), protease inhibitor (ROCHE), 1 mM phenylmethylsulfonyl fluoride (PMSF) and 15 
mM NaVanadate for 30 min. Equal amounts of protein (20 µg) were loaded on 12% 
polyacrylamide gels. After electrophoresis, the gels were blotted onto nitrocellulose 
membranes. Membranes were then incubated with anti-galectin-3 antibody (Thermo Fisher 
Scientific, Landsmeer, The Netherlands), anti-Hsp47 antibody (#ab109117, Abcam, 
Cambridge, UK), anti-mac-2 antibody (CL8942AP, Cedarlanelabs, USA), troponin T (T6277, 
Sigma, Netherlands), anti-vimentin antibody (V5255, Sigma, Netherlands), anti-CD68 
antibody (ab76308, Abcam, Cambridge, UK) and anti-GAPDH antibody (10R-G109a, 
Fitzgerald, USA) overnight at 4° C. Membranes were washed and incubated with the 
appropriate secondary HRP-conjugated antibody and signals were visualized with ECL and 
analyzed with densitometry (Syngene, Cambridge, United Kingdom).4,14,15 
 
Human adult dermal fibroblast culture experiments 
Human adult dermal fibroblasts (primary cells) were cultured for 72 hours in culture 
medium (EMEM containing 1% Pen/Strep, 1% L-glutamine, 0.5% FCS and 0.173 mM 
ascorbid acid 2-phosphate) with or without galectin-3 (10 µg/mL; #450-38, Preprotech, Rocky 
Hill, NY, USA), N-Lac (10 mM) or a combination. The initial seeding density was 15,000 
cells/cm2. Cells were harvested and RNA was isolated. cDNA synthesis was conducted using 
RevertAid First Strand cDNA Synthesis Kit  (#K1622, Fermentas, St. Leon-Rot, Germany) 
and cDNA was hybridized to a custom made low density array carrying probes for ~50 genes 
involved in fibrosis (collagen production, collagen cross-linking, collagen processing and 
collagen degradation). The complete list of gene is presented in Table S4 of the Supplemental 
data. Genes that were most significantly expressed (LOXL2, HSP47, PCOLCE, COL1A1, 
COL1A2, COL3A1, and P4HB) were verified using quantitative RT-qPCR and normalized 
against the reference gene GAPDH. In addition, vimentin staining, a fibroblast marker, was 
carried out with anti-vimentin (C-20; Santa Cruz Biotechnology, Santa Cruz, CA, USA) and 
protein levels of collagen type 3 were measured with ELISA (human collagen 3 ELISA kit, 
#Hu9614, TSZ Scientific LLC, Framingham, MA, USA). Collagen type 3 protein levels were 




Analyzes of galectin-3 expression in macrophages and in adult rat cardiac myocytes and 
fibroblast 
Adult rat cardiomyocytes and fibroblasts were isolated using a Langendorff perfusion 
system with retrograde perfusion.16 The perfusion solution (10 mM HEPES (pH 7.4), 133.5 
mM NaCl, 4.0 mM KCl, 1.2 mM NaH2PO4, 1.2 mM MgSO4, 20 µM CaCl2) contained 
0.2mg/ml Liberase TM Research Grade (Roche) to digest the extracellular matrix. 
Cardiomyocytes were subsequently separated from other cells by several rounds of velocity 
sedimentation in a perfusion solution containing 1mg BSA/ml. Adult cardiomyocytes were 
directly frozen after isolation. Cardiac fibroblasts were cultured for several days in DMEM 
medium supplemented with 10% FCS and penicillin-streptomycin (100 IU/ml and 100ug/ml, 
respectively) to obtain sufficient cells for analysis. A rat alveolar macrophage cell line17 was 
also cultured in the same medium. Cell lysates were generated as described in the Western 























Table S1. List of primers used for RT-qPCR in mice 
 RT-qPCR primer, 5’ to 3’  
Gene symbol (name) Forward Reverse 
Nppa (ANP) ATGGGCTCCTTCTCCATCAC TCTACCGGCATCTTCTCCTC 
Lgals3 (Galectin-3) TATCCTGCTGCTGGCCCTTATG GTTTGCGTTGGGTTTCACTG 






Table S2. List of primers used for RT-qPCR in rats 
 RT-qPCR primer, 5’ to 3’  
Gene symbol (name) Forward Reverse 
Nppa (ANP) ATGGGCTCCTTCTCCATCAC TCTACCGGCATCTTCTCCTC 
Lgals3 (Galectin-3) CCCGCTTCAATGAGAACAAC ACCGCAACCTTGAAGTGGTC 
Loxl2 TGACTGCCAGTGGATAGAC ATGCGGTAGCCATCATAGC 
Hsp47 TCATGGTGACCCGCTCCTAC GCTTATGGGCCAAGGGCATC 
Pcolce GAAGAAAGGAGCCAGTTACC GGGCACTTTCTCTTGCTTAG 
Col1a1 ACAGCGTAGCCTACATGG AAGTTCCGGTGTGACTCG 
Col1a2 ATGGTGGCAGCCAGTTTG GCTGTTCTTGCAGTGGTAGG 
Col3a1 TGGAAACCGGAGAAACATGC CAGGATTGCCATAGCTGAAC 
P4hb ACCAGCGCATACTTGAGTTC ACTCCGGTTTGTACTTGGTC 
Gapdh CATCAAGAAGGTGGTGAAGC ACCACCCTGTTGCTGTAG 
Mmp2 TGAGCTCCCGGAAAAGATTG CATTCCCTGCGAAGAACACA 
Mmp9 CGGGAACGTATCTGGAAATTCG CATGGCAGAAATAGGCCTTGTC 
Timp1 AGAGCCTCTGTGGATATGTC CTCAGATTATGCCAGGGAAC 








Table S3. List of primers used for RT-qPCR in human cell culture experiments 
 RT-qPCR primer, 5’ to 3’ 
Gene symbol (name) Forward Reverse 
LOXL2 CCGCATCTGGATGTACAAC TTAAGAGCCCGCTGAAGTG 
HSP47 CTTCATGGTGACTCGGTCCT CGATTTGCAGCTTTTCCTTC 
PCOLCE CTGTTCCTGGCACATCATC CTTGTAGGAGGCTGAGAAG 
COL1A1 GCCTCAAGGTATTGCTGGAC ACCTTGTTTGCCAGGTTCAC 
COL1A2 CTGGAGAGGCTGGTACTGCT AGCACCAAGAAGACCCTGAG 
COL3A1 CTGGACCCCAGGGTCTTC CATCTGATCCAGGGTTTCCA 
P4HB TTGATGAAGGCCGGAACAAC TCTGCTCGGTGAACTCGATG 
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Supplemental figures and figure legends 
 
Figure S1. Strategy for the genetic disruption of galectin-3 in mice and analysis of galectin-3 expression. 
 
Figure S1 Shows schedule of creation of galectin-3 knock-out (Gal3-KO) mice and expression of galectin-3 in 
the different mouse groups. (A) Exon 2, 3 and 4 were disrupted in the Gal3-KO mice. (B) mRNA expression of 
galectin-3 in the left ventricles of mice from the different experimental groups (n= 7-12). (C) Representative 
Western blot showing galectin-3 expression (anti-MAC-2) in left ventricles of mice from the different 
experimental groups. (D) Quantification of Western blot (n=5 ). Con: control (saline-infused); AngII: angiotensin 
II; sham: sham-operated mice; TAC: transverse aortic constriction. * P<0.05 vs. WT-con (BON, M=6 tests), ‡ 
P<0.05 vs. WT-AngII (BON, M=6 tests), § P<0.05 vs. WT-sham (BON, M=6 tests), ** P<0.05 vs. WT-TAC 
(BON, M=6 tests). 
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Figure S2. Survival of REN2 rats in the different groups. 
 
Figure S2 shows the survival of REN2 rats in the different experimental groups. In the REN2-con group, 7 out of 
18 rats (39%) died and 1 out of 10 rats (10%)died in the REN2-Gal3i group. No SD control animals died (SD-
con group). Con: control; Gal3i: galectin-3 inhibitor. 
 
 
Figure S3. Localization of galectin-3 expression in cardiac tissue. 
 
Figures S3 shows the localization of galectin-3 in cardiac tissue from REN2 and SD rats. Immunohistochemical 
analysis showed that galectin-3 immunoreactivity (red-brown color) is predominantly observed at interstitial sites 
but not in cardiomyocytes. Con: control; Gal3i: galectin-3 inhibitor. 
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Figure S4. Localization of galectin-3. 
 
Panels A-C: Lower magnification (20X) showing double labeling for galectin-3 (red), the macrophage marker 
ED1 (green) and the merged image with DAPI staining nuclei (blue) in the different experimental groups. Panel 
D: higher magnification (40X) of the merged image of galectin-3, the macrophage marker ED1 and DAPI (blue). 
Panels E-G: Lower magnification (20X) showing double labeling for galectin-3 (red), the fibroblast marker 
collagen III (green) and the merged image with DAPI staining nuclei (blue) in the different groups. Panel H: 
higher magnification (40X) of the merged image of galectin-3, the fibroblast marker collagen III and DAPI (blue). 
Con: control; Gal3i: galectin-3 inhibitor. 
 
Figure S5. Protein expression of galectin-3 in cardiomyocytes, fibroblasts and macrophages. 
     
Figure S5 shows a Western blot with lysates from different cell types. Galectin-3 was detected using anti-
galectin-3, anti-troponin T (cardiomyocyte marker), anti-Vimentin (fibroblast marker) and anti-CD68 
(macrophage marker) antibodies and an anti-GAPDH antibody (as loading control). CMC = adult rat 
cardiomyocyte; FB = fibroblast and macrophage = a rat alveolar macrophage cell line. 
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Figure S6. Extracellular matrix protein gene expression in rat hearts. 
 
Figure S6 shows changes in gene expression of extracellular matrix proteins in rat hearts as determined by RT-
qPCR. (A) Timp1, (B) Timp2, (c) Mmp2 and (d) Mmp9. Gal3i: galectin-3 inhibitor. †† P<0.05 SD-con vs. 
REN2-con (BON, M=3 tests), §§ P<0.05 SD-con vs. REN2-Gal3i (BON, M=3 tests). 
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Background: Galectin-3 activation has been implicated in renal damage and fibrogenesis. 
Limited data are available to suggest that galectin-3 targeted intervention acts as a potential 
therapeutic candidate for the prevention of chronic kidney disease (CKD).  
Methods: We used homozygous TGR(mREN)27 rats (REN2), which develop severe high 
blood pressure around 4 weeks of age and heart failure at 13-15 weeks of age. Six-week-old 
male REN2 rats were treated with a galectin-3 blocking compound, N-acetyllactosamine 
(Gal3i), for 6 weeks. Untreated REN2 and SD rats served as controls. We measured cardiac 
function with echocardiogram and invasive hemodynamics prior to sacrifice. Blood pressure 
and proteinuria were measured at 0, 3 and 6 weeks. Plasma creatinine was determined at 6 
weeks. Renal damage was assessed using histological scores: focal glomerular sclerosis (FGS), 
glomerular desmin expression, glomerular and interstitial macrophage numbers and alpha 
smooth muscle actin expression. Inflammatory cytokines and extracellular matrix proteinases 
were quantified by RT-qPCR.  
Results:  Systolic blood pressure was consistently higher in untreated REN2 rats compared 
with SD rats and was not affected by Gal3i treatment. Plasma creatinine and proteinuria were 
significantly increased in untreated REN2 rats and this was reduced by treatment with Gal3i. 
Parameters of renal damage were also elevated in untreated REN2 rats except for glomerular 
macrophage scores. All these parameters were reduced upon Gal3i treatment. Various 
inflammatory cytokines were elevated in untreated REN2 rats and attenuated by Gal3i. 
However, markers of extracellular matrix turnover were marginally altered in untreated REN2 
rats as compared to SD rats.  
Conclusion: Pharmacological inhibition of galectin-3 attenuates hypertensive nephropathy, as 
indicated by a reduction in proteinuria, preservation of renal function and a decrease in renal 
damage. Drugs binding to galectin-3 may be potential therapeutic candidates for the 
prevention of chronic kidney disease (CKD). 
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Renal impairment is frequently observed in cardiovascular disease (1, 2). Chronic kidney 
disease (CKD), defined as progressive loss of renal function over a period of month or years, 
is characterized at the level by glomerular sclerosis and interstitial fibrosis (5). CKD 
represents a significantly global health problem (3, 4). Early detection and prevention of CKD 
could improve both renal and cardiovascular morbidity and mortality. Glomerular sclerosis is 
an important factor in the progression of chronic kidney injury. Accordingly, drugs that aim to 
protect against glomerular injury can be of great value. 
Galectin-3 belongs to the galectin-3 family of mammalian lectins and is characterized by 
a carbohydrate recognition domain (CRD) that has affinity for β-galactosides. Galectin-3 
mediates cell-cell and cell-matrix interactions by binding to lactosamine-containing 
glycoconjugates via its CRD (6). There is accumulating evidence that galectin-3 plays an 
important role in inflammatory and fibrotic processes (7). Upregulation of galectin-3 is 
involved in various types of organ fibrosis. Macrophage derived galectin-3 induces 
myofibroblast activation, promotes collagen synthesis, deposition and subsequently leads to 
fibrosis. Moreover, previous research showed that binding of modified citrus pectin (MCP) to 
the galectin-3 CRD exerts beneficial effects in experimental acute kidney injury (8).  
Transgenic TGR (mRen2)27 (REN2) rats exhibit persistent high blood pressure, 
progressive proteinuria and nephropathy that strongly resembles the human situation: injury 
and dysfunction of glomerular endothelial cells, micro-inflammation, excessive production of 
extracellular matrix (ECM), which eventually results in glomerular sclerosis (9, 10). This 
collective of inflammation, glomerular sclerosis, tubular interstitial fibrosis, and proteinuria 
are all early markers for progressive renal dysfunction in CKD (11, 12) Previous experimental 
and clinical studies demonstrate that proteinuria caused by hypertension could almost be 
totally reversed by angiotensin converting enzyme (ACE) inhibitor (13, 14), whereas other 
experimental studies showed that reduction in proteinuria was partially independent of blood 
pressure level (15-17).  
In the present study, we examined the effects of pharmacological inhibition of galectin-3 
by N-acetyllactosamine (N-lac, Gal3i) on progressive glomerulosclerosis and proteinuria in 
hypertensive REN2 rats.  
 
Materials and methods 
Animals 
We studied 6-week-old, male, homozygous, TGR (mREN2)27 rats (denoted as REN2). 
These rats show a phenotype of severe hypertension and left ventricular (LV) hypertrophy, 
leading to heart failure (HF) at 13-15 weeks of age (18). Rats were bred at the MaxDelbrück 
Center for Molecular Medicine (Berlin, Germany). Male age-matched Sprague-Dawley (SD) 
rats were used as control (Harlan, The Netherlands). Animals were housed under standard 
conditions. The study was approved by the Animal Ethical Committee of the University of 
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Groningen, the Netherlands, and was conducted in accordance with existing guidelines for the 
care and use of laboratory animals.  
 
Experimental design 
To study the effects of galectin-3 inhibition on renal protection, we allocated SD rats and 
REN2 rats to control treatment or treatment with the galectin-3 inhibitor. Rats were treated 
with an established inhibitor of galectin-3, N-Acetyllactosamine (N-Lac), in a final dose of 5 
mg/kg/day. Injections were administered intraperitoneally, three times per week. Three 
different groups were studied: SD-control (N=5), Ren-2-control (N=5), Ren-2-Gal3-inhibitor 
(N=10). Rats were placed in metabolic cages during 24 hours at baseline and at 3 and 6 weeks 
and urine samples were collected for determination of urinary protein. Systolic blood pressure 
(SBP) was measured using a noninvasive tail-cuff method using a computer-assisted 
oscillatory detection device (Apollo 179; IITC Life Science, Woodland Hills, California, USA) 
at week 0, 3 and 6 after treatment, Rats were sacrificed 6 weeks after initiation of the 
experiment. 
 
Measurement of cardiac and hemodynamic function  
Cardiac function was assessed by echocardiography at baseline and prior to sacrifice 
(Vivid 7, GE Healthcare, Chalfont StGiles, UK; equipped with a 10-MHz (rats) phase array 
linear transducer, as described (19). Hemodynamic function was assessed invasively, as 
previously described (20), by introducing a 1.4 French microtip pressure-volume transducer 
(Millar Instr. Inc., Houston, TX, USA) via the right carotid artery into the aorta. A three-
minute period was allowed for stabilization before systolic and diastolic blood pressure and 
heart rate (HR) were recorded (average of 20 heart cycles). Other parameters that were 
measured include peak systolic blood pressure (SBP) and LV end diastolic pressure (LVEDP). 
 
Tissue and plasma processing 
After measuring hemodynamics, arterial blood was drawn and collected. Samples were 
centrifuged at 3000 rpm for 15 min at 4°C, and plasma was frozen for creatinine analysis. 
Kidneys were removed and their weight was determined. Transversally cut kidneys were 
snapping frozen or fixed in buffered formalin (3.7%) for 24 hours, dehydrated and embedded 
in paraffin.  
 
Immunohistochemistry  
Paraffin sections were dewaxed and subjected to an antigen retrieval procedure by 
overnight incubation at 80°C in 0.1M Tris/HCL, pH 9.0. Sections were subsequently washed 
three times with PBS, endogenous peroxidase was blocked with 0.075% H2O2 in phosphate 
buffered saline (PBS, pH 7.4) for 30 minutes and incubated with the following primary 
antibodies: the myofibroblast marker alpha smooth muscle actins, α-SMA (clone 1A4, Sigma 
Aldrich, St.Louis, MO, USA); the macrophage marker ED1(#MCA341R, AbDSerotec, 
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Oxford, UK); the tubular damage marker Kim-1 (a gift from Victoria Bailly, Principal 
Scientist, Cambridge, UK); and the glomerular epithelial marker desmin(Dakopatts, DAKO, 
Golostrup, Denmark). All incubations with primary antibodies were in 1% BSA/PBS for 1 
hour at room temperature. Binding was detected using sequential incubation with appropriate 
peroxidase labeled  secondary and tertiary antibodies diluted in 1% BSA/PBS buffer and 1% 
normal rat serum for 30 minutes, peroxidase activity was developed by using 3,3’-
diaminobenzidine tetrachloride for 10 min containing 0.03% H2O2. Ultimately, 
counterstaining was performed using Mayer’s hematoxilin. All sections were digitalized using 
a scanning system at 20x magnification (Nanozoomer 2.0-HT, Hamamatsu, Japan). α-SMA 
and Desmin staining were quantified with Scanscope software (Aperio Technologies version 9, 
Vista, CA, USA). Kim-1 staining was similarly analyzed in the entire renal cortex. The 
number of both glomerular (50 glomeruli) and interstitial macrophages (30 interstitial fields) 
was manually counted by a blinded observer. Additionally, kidney sections were stained with 
periodic acid-schiff (PAS) and scored for focal glomerular sclerosis (FGS). FGS was scored 
positive if all of the following features were present: collapse of capillaries, mesangial matrix 
expansion, and adhesion of the glomerular visceral epithelium to Bowman’s capsule. A score 
for the degree of affected glomeruli was applied as follows: unaffected glomeruli were scored 
as 0; 0-25% affected glomeruli was scored as 1, 25-50% affected was scored as 2, 50-75% 
affected was scored as 3 and if all glomeruli were positive (75-100%) for FGS, a score of 4 
was given. The ultimate score (%) is obtained by dividing the total score by the number of 
glomeruli times one hundred (21).  
 
Quantitative real-time PCR 
cDNA synthesis was performed using 0.5 µg total RNA (Quantitect Rev. Transcriptase 
kit, Qiagen, Venlo, The Netherlands) as described previously (19, 22). Quantitative real-time 
PCR (RT-qPCR) was performed using SYBR Green mix (Absolute SYBR Green ROX mix, 
Thermo Scientific, Breda, the Netherlands) on CFX384 Real-Time PCR Detection System 
(Bio-Rad Laboratories, Veenendaal, the Netherlands). All targets gene expression level of 
inflammation cytokines and extracellular matrix turnover proteins (a list of primers used for 
RT-qPCR showed in supplemental table 1) were evaluated under the same reaction conditions: 
95°C for 15 minutes, then 36 cycles of 95°C for 15 seconds and 60°C for 30 seconds. Samples 
were analyzed with quantification software (Bio-Rad CFX Manager 1.6). mRNA levels were 
expressed in relative units based on a standard curve obtained with serial dilutions of a 
calibrator cDNA mixture. Gapdh expression was used to normalize all expression data. 
 
Statistical analysis 
Data are expressed as mean ± SEM. Means were compared using one -way ANOVA with 
a Dunnett post hoc test, using untreated REN2 rats as a comparator.  All calculations were 
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Characteristics of REN2 rats  
REN2 rats developed severe hypertension (>200mmHg) at 6 weeks of age; SBP was 
significantly increased compared to SD rats at all-time points (0, 3, 6 weeks, Table 1 and 
Figure 1b). There was no difference in SBP between the untreated REN2 and Gal3i treated 
REN2 rats (217±7 vs. 235±6 mmHg, P=NS) (Figure1b). Ren2 rats had lower body weights 
compared to SD rats. Cardiac and hemodynamic measurements prior to sacrifice showed a 
significant decrease in fractional shortening (FS) and an increase in LVEDP in REN2 rats 
compared to SD rats (34±1% vs. 44±2% and 9±1 vs. 4±1 mmHg, P<0.05) (Table1). The 
untreated REN2 rats develop LV dysfunction. Treatment with Gal3i attenuated LV 
dysfunction by interfering with myocardial fibrogenesis (unpublished data) (Table1).  
 
Renal function 
Renal function was impaired in REN2 rats, as shown by a marked increase in proteinuria, 
plasma creatinine and an associated decrease in renal clearance after 6 weeks of the treatment 
(proteinuria: 81±18 vs. 26±1 mg/24h; plasma creatinine: 45±5 vs. 26±2 µmol/L; renal 
clearance: 2.1±0.1 vs. 4.0±0.3 mL/24h, P<0.05) (Table 1, Figure 1c-e).   
 
Galectin-3 inhibition prevents progression hypertensive kidney injury  
Figure 1 Renal function in 
rats. Outline of the 
experimental protocol of the 
prevention studies in rats (a). 
Changes in systolic blood 
pressure of rats, as assessed by 
tail-cuff measurements at week 
0, 3 and 6 (b). Proteinuria 
measurements at week 0, 3 and 
6 (c). Plasma creatinine at 
sacrifice (week 6) (d). 
Calculated creatinine clearance 





Proteinuria was increased in the untreated REN2 rats compared with SD rats, but the 
increase was attenuated in the Gal3i treated REN2 rats (16±2 vs. 81±19 mg/24h in untreated 
REN2 rats, P<0.05) (Figure1c). Also, a marked increased level of plasma creatinine was  
found in untreated REN2 rats, and this was also attenuated after treatment with the Gal3i 
(27±2 vs. 45±5 µmol/L in the untreated REN2 rat, P<0.05) (Figure1d). Creatinine clearance 
was clearly decreased in the untreated REN2 rats compared with SD rats, which was 
attenuated after treatment with Gal3i (2.8±0.4 vs. 2.2±0.1 ml/24h in the untreated REN2 rat, 
P<0.05) (Figure1e).   
 
Galectin-3 inhibition protects renal damage  
In untreated REN2 rats, FGS was significantly higher as compared to SD rats (15 ±4% vs. 0 % 
in SD rats, P<0.05). Gal3i treatment resulted in a significant attenuation of FGS (3 ±1% vs. 
15±4% in untreated REN2 rat, P<0.05) (Figure 2a, b, c and g). Additionally, glomerular 
desmin expression was markedly increased in untreated REN2 rats (21±1 vs. 5±1 in SD rats, 
P<0.05), which was attenuated after Gal3i treatment (14±2 vs. untreated REN2 rat, P<0.05) 
(Figure 2d, e, f and h).  
 
Galectin-3 inhibition suppresses renal inflammatory response 
Persistent systemic hypertension induces glomerular micro-inflammation (9). We 
observed that the number of interstitial macrophages was significantly increased in the 
untreated REN2 rats as compared to SD rats, while the number of glomerular macrophages 
 
 
Figure 2  Glomerular 
morphology in the rat kidney. 
Representative pictures of 
focal glomerular sclerosis with 
PAS staining are shown for 
SD, untreated REN2, and 
Gal3i-treated REN2 rats (a-c). 
Glomerular desmin expression 
in SD, untreated REN2, and 
Gal3i-treated REN2 rats (d-f). 
The quantified percentages of 
focal glomerular sclerosis (g) 
and desmin expression (h). * 
P<0.05 vs. REN2-con 
 






was not changed in the untreated REN2 group (Figures 3a, 3b, 3d, 3e, 3g, and 3h). Gal3i 
treatment attenuated macrophage influx in both the glomerular and the interstitial 
compartment (Figures3c, 3f, 3g and 3h). CD68 (macrophages), interleukin-6 (Il-6) and other 
relevant inflammatory cytokines e.g. galectin-3 and monocyte chemoattractant protein 1 
(Mcp-1) were subsequently determined by RT-qPCR (Figure3i-l). Galectin-3, Il-6 and Mcp-1 
were all significantly increased in untreated REN2 rats and reduced by the treatment with  
Figure 3 Inflammatory 
cells and markers in rat 
kidney. Representative 
pictures of glomerular 
macrophages in SD, 
untreated REN2, and 
Gal3i-treated REN2 rats 
are shown (a-c). Typical 
examples of macrophage 
infiltration in the tubulo-
interstitial space of SD, 
untreated REN2, and the 
Gal3i-treated REN2 rats 
(d-f). Quantification of the 
number of glomerular 
macrophages (g) and 
macrophages in tubulo-
interstitial space (h). 
Inflammatory markers were 
quantified by RT-qPCR 
and corrected for Gapdh 
expression. Fold 
differences are shown for: 
Galectin-3 (i), Cd68 (j), 
Interleukin-6 (K) and Mcp-








Gal3i. Cd68 mRNA level was not altered in the untreated REN2 group as compared to the SD 
group. Gal3i treatment did, however, attenuate Cd68 expression, which is in line with the 
decreased glomerular and interstitial influx of macrophages in this animal group.   
 
Matricellular protein changes and in early stages of kidney injury  
α-SMA expression, as investigated by IHC and RT-qPCR was significantly increased in 
untreated REN2 rats as compared to SD rats.  Gal3i caused a reduction in α-SMA IHC-
staining and mRNA levels (Figures 4a-c, 4g and supplemental figure 1a). Also, a decrease in 
KIM-1 protein expression was observed after Gal3i treatment (Figures 4d-f) and Kim-1 
mRNA expression was similarly decreased (Figure 4h). Additionally, the mRNA levels of 
Tgf-β, Mmp2 and Timp2 were not altered in the untreated REN2 group as compared to the SD 
group (Supplemental figures 1b, 1c and 1f). Interestingly, Mmp9 tends to show a lower 
expression in both untreated and treated REN2 groups as compared to the SD group 
(Supplemental figure 1d). Furthermore, Timp1 expression was significantly increased in the 
untreated REN2 group and decreased when treated with Gal3i (Supplemental figure 1e). 
Finally, we found that mRNA expression of extracellular matrix collagen proteins Col1a1 and 
Col3a1 were not different between the untreated REN2 and the SD groups, but significantly 
decreased when treated with Gal3i (Supplemental figures 1g and 1h).  
 
Figure 4 Renal tubular and 
interstitial changes in rat 
kidney. Representative pictures 
of tubulo-interstitial α-SMA 
staining in SD, untreated 
REN2, and Gal3i-treated REN2 
rats (a-c). Typical examples of 
tubular damage marker KIM-1 
staining in SD, untreated 
REN2, and Gal3i-treated REN2 
rats (d-f). Quantification of α-
SMA staining (g) and KIM-1 
mRNA expression (h). * 
P<0.05 vs. REN2-con 
 




The major finding of the present study study is that targeted inhibition of galectin-3 
attenuates renal structural and functional deterioration in REN2 rats with hypertensive end 
organ damage and increased plasma galectin-3 levels. Over a six weeks course, the untreated 
REN2 rats developed substantial proteinuria which was associated with the development of 
glomerulosclerosis. Treatment with Gal3i almost completely prevented the development of 
proteinuria and attenuated fibrogenesis and inflammation, as determined by histological 
staining and gene expression analysis. Interestingly, hypertension is not altered in REN2 rats 
treated with the Gal3i, indicating that the positive effects of the treatment are blood pressure 
independent. 
Galectin-3 is expressed in various organs, including heart, lung, liver and kidney (7). The 
role of galectin-3 in fibrosis and inflammation has been partially elucidated in recent years. In 
a mouse model of unilateral ureter obstruction (UUO), characterized by severe hydronephrosis, 
inflammation and fibrosis galectin-3 disruption (Gal-3 KO mice) resulted in decreased renal 
inflammation. This was associated with a reduced pro-fibrotic response as evidenced by a 
decreased collagen production and deposition (23). Another study in UUO-induced renal 
injury also reported reduced myofibroblast activation as determined by decreased α-SMA 
staining in Gal-3 KO mice as compared to wild type mice. Surprisingly, they observed 
increased interstitial collagen deposition in these mice and decreased E-cadherin levels, a 
surrogate marker for tubular damage (24). Unfortunately, no explanation is given for this 
paradoxical result of less interstitial myofibroblasts and less procollagen I expression, but 
more fibrosis (collagen deposition). These remarkable effects may occur at the late stages (2-3 
weeks induction) of the UUO model, since Henderson et al., who investigated an earlier time 
point (7 days) after UUO-induced kidney injury observed both less myofibroblasts and less 
fibrosis in Gal-3 KO mice. In a model of folic acid induced kidney fibrosis it was shown that 
treatment with modified citrus pectin (MCP), a compound that binds to the galectin-3 
carbohydrate recognition domain (CRD), attenuated macrophage influx and renal fibrosis (8). 
Together with our results, which reveal Gal3i mediated attenuation of inflammatory responses 
(e.g. CD68, IL-6 and MCP-1), macrophage infiltration and myofibroblast activationin a 
hypertensive rat model, there is strong support for a protective role for galectin-3 inhibition in 
different models of renal damage.  Future studies require the analysis of long-term treatment 
effects and the effects of Galectin-3 inhibition in established kidney disease. 
TGF-β is an important mediator of myofibroblast activation (25, 26) and it was 
demonstrated that macrophage derived galectin-3 directly induces myofibroblast activation 
resulting in up-regulation of collagen synthesis (23, 27).  We did not observe altered renal 
expression of Tgf-β mRNA in our hypertensive rat model and Gal3i treatment did also not 
affect TGF-β expression. This is in line with previous observations (23). This suggests that in 
our model TGF-β may not be the main driving force for fibrogenesis and that galectin-3 does 
not affect the expression of TGF-β. Gal3i did, however, lower the expression of several other 
genes involved in extracellular matrix (ECM) remodeling, including Timp1 and Col1a1 and 
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Col3a1. The expression of the metalloproteases Mmp2 and Mmp9 was not altered by Gal3i 
treatment, indicating that galectin-3 inhibition alters the expression of a limited number of 
ECM genes independent of TGF-β modulation.   
Numerous studies have shown that anti-hypertensive therapy can slow down the decline 
in renal dysfunction, (28, 29), although other experimental studies have shown that a 
reduction in proteinuria can be mediated independent of blood pressure. Intervention with 
tranilast, an inhibitor of TGF-β, shows beneficial effects on proteinuria and tubulointerstitial 
damage independent of blood pressure in streptozotocin induced diabetic REN2 rats (15). 
Also, statin treatment reduces glomerular inflammation and podocyte damage in experimental 
deocycoricosterone-acetate (DOCA)-salt hypertensive rats (16). Moreover, arrest-specific 
protein 6 (Gas6) is involved in cardiac and renal injury, and Gas6 deficiency reduced renal 
inflammation, fibrosis and cardiac remodeling independent of blood pressure (17). 
Collectively, the above mentioned studies, together with our galectin-3 inhibitory study 
indicate that renal protection can be reached not only by lowering blood pressure levels, but 
also by specific anti-fibrotic and anti-inflammatory treatments.  
 
Conclusion 
Our study shows that pharmacological inhibition of galectin-3 attenuates impaired CKD 
in a hypertensive rat model. Galectin-3 inhibition attenuates myofibroblast activation and 
inflammation resulting in reduced fibrogenesis. This improves glomerular filtration function 
and reduces proteinuria. Therefore, we conclude that galectin-3 inhibition exerts its protective 
effects by directly acting on the renal glomeruli, parenchyma and tubuli and is independent of 
blood pressure. These new findings warrant further studies using galectin-3 inhibition as a 
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Table S1. List of primers used for RT-qPCR in rats renal 
 RT-qPCR primer, 5’ to 3’  
Gene symbol (name) Forward Reverse 
Lgals3 (Galectin-3) CCCGCTTCAATGAGAACAAC ACCGCAACCTTGAAGTGGTC 
α-SMA  CATCATGCGTCTGGACTTGG TCACGCTCAGCAGTAGTCAC 
Cd-68 CTCTCATCATTGGCCTGGTC GGGCTGGTAGGTTGATTGTC 
Il-6 (Interleukin-6) CCCACCAGGAACGAAAGTCA TCTTGCGGAGAGAAACTT 
Mcp-1 CCGACTCATTGGGATCATCTT TGTCTCAGCCAGATGCAGTTAAT 
Kim-1 AGAGAGAGCAGGACACAGGCTT ACCCGTGGTAGTCCCAAACA 
Tgf-β AAGAAGTCACCCGCGTGCTA TGTGTGATGTCTTTGGTTTTGTCA 
Col1a1 ACAGCGTAGCCTACATGG AAGTTCCGGTGTGACTCG 
Col3a1 TGGAAACCGGAGAAACATGC CAGGATTGCCATAGCTGAAC 
Mmp2 TGAGCTCCCGGAAAAGATTG CATTCCCTGCGAAGAACACA 
Mmp9 CGGGAACGTATCTGGAAATTCG CATGGCAGAAATAGGCCTTGTC 
Timp1 AGAGCCTCTGTGGATATGTC CTCAGATTATGCCAGGGAAC 
Timp2 TGGACGTTGGAGGAAAGAAG TGTCCCAGGGCACAATAAAG 





Figure S1 Gene expression of ECM proteins changed in rat kidney. α-SMA(a), Tgf-β(b), Mmp2(c), Mmp9(d), 
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Aims - Galectin-3 plays an important role in fibrogenesis. Furthermore, increased galectin-3 
levels are associated with poor survival in patients with heart failure (HF). We examined the 
correlation of plasma galectin-3 levels with cardiopulmonary aerobic capacity and renal 
function in patients with chronic HF. 
Methods and results - We measured plasma galectin-3 in 99 patients with stable chronic HF 
with New York Heart Association (NYHA) class II-IV. All patients had left ventricular 
ejection fraction (LVEF) ≤45% and an ability to undergo cardiopulmonary exercise testing. In 
the present HF cohort, plasma galectin-3 levels were divided in quartiles (quartile 1: <12.65 
ng/mL; quartile 2: 12.65-14.34 ng/mL; quartile 3: 14.35-18.67 ng/mL; quartile 4: >18.67 
ng/ml). High galectin-3 levels were associated with poor renal function (consisted of 
increased creatinin (p=0.026); increased urea (p=0.01); decreased eGFR (p=0.01), increased 
NT-proBNP (p=0.008), and decreased peak VO2 (p=0.038). Linear regression analysis 
showed a correlation between the plasma galectin-3 levels and peak oxygen uptake (VO2 max), 
p=0.016; and renal function (p=0.002). However, after adjustment for age and gender, the 
correlation between galectin-3 and VO2 max and renal function was lost. 
Conclusions - high plasma galectin-3 levels are associated with poor renal function and lower 
aerobic capacity in patients with chronic HF. 
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Heart failure (HF) is a serious medical disease and an epidemiological problem. It is 
characterized by high morbidity and mortality [1-3]. The pathophysiologic mechanisms of HF 
appear to be the results of interaction between cardiac remodeling, neurohormonal peptides 
(e.g. N-terminal pro brain natriuretic peptide (NT-proBNP)), inflammation, and different 
biomarkers [4-6]. Accumulated experimental studies reported that macrophage-derived 
galectin-3 plays important regulatory roles in inflammation and fibrotic processes in the 
development cardiac remodeling and chronic HF [4-6]. Additionally, clinical evidence 
showed that plasma galectin-3 levels are increased in patients with acute and chronic HF [7-
14]. The PRIDE study revealed that plasma galectin-3 was a superior predictor for 60-day 
mortality compared to NT-proBNP [11]. Subsequently, high plasma galectin-3 levels were 
associated with left ventricular filling and diastolic function [7]. Furthermore, in patients with 
chronic stable and acute decompensated HF, increased plasma galectin-3 levels were linked to 
renal dysfunction and lower peak oxygen uptake (VO2 max) [8, 11, 15]. In the DEAL-HF 
study, plasma galectin-3 levels were increased in patients with higher NT-proBNP levels, 
which were in turn correlated with lower estimated glomerular filtration rate (eGFR) and 
lower VO2 max [13]. Furthermore, higher levels of galectin-3 were found in patients with 
renal dysfunction as compared to patients with normal renal function. As a substantial part of 
chronic HF patients have decreased renal function, we examined the correlation of plasma 




Patients and study design  
The data described and used in this manuscript is derived from the BENEFICIAL study 
(Effects of alagebrium, an advanced glycation end product breaker, on exercise tolerance and 
cardiac function in patients with chronic heart failure, NTC00516646) [16-18]. The study 
design, baseline characteristics, inclusion and exclusion criteria have been published 
previously [16-18]. Data of all 99 patients who were recruited from the University Medical 
Center Groningen, the Netherlands and three other regional affiliated hospitals were analyzed 
in this sub study. Briefly, patients with New York Heart Association (NYHA) class II-IV had 
to have stable chronic HF for at least three months, and a documented left ventricular ejection 
fraction (LVEF) <45%. Main exclusion criteria were the inability of patients to undergo 
exercise testing, cardiac resynchronization therapy, pacemaker therapy, active and/or treated 
malignancies within 12 months prior to inclusion, and clinically significant renal dysfunction. 
The efficacy measurements included echocardiography and cardiopulmonary aerobic capacity 
testing. The BENEFICIAL study was approved by the Medical Ethical Committee of the 





Two-dimensional echocardiography was performed by experienced cardiac technicians 
using a General Electric VIVID 7 system with a 2.5-3.5 MHz probe (Horton, Norway). Left 
ventricular dimensions were measured. Diastolic function was evaluated with peak early (E) 
and late (A) diastolic filling velocities, isovolumetric relaxation time (IVRT) and deceleration 
time (Dct) of the early peak filling. Early diastolic tissue velocity (E') was measured on the 
lateral and septal wall areas, using color-coded tissue Doppler imaging (CC-TDI). E/E' was 
calculated by dividing the peak early diastolic filling (E) by the average E'. Diastolic 
dysfunction was defined as an E/E' >10. Systolic dysfunction was determined by Simpson’s 
LVEF and defined as a LVEF ≤45%. If Simpson’s LVEF could not be determined, LVEF was 
estimated by eyeballing [16-18]. 
 
Cardiopulmonary aerobic capacity testing 
Cardiopulmonary aerobic capacity testing was performed using a care fusion, Master 
screen CPX (Houten, The Netherlands) according to a modified Bruce protocol [19], which 
increases the workload more gradually than the Bruce protocol [20]. The first stage was 
performed at 1.7 mph and 0% grade, the second stage at 1.7 mph and 5% grade, and the third 
stage corresponds to the first stage of the Bruce protocol. A standard 12 lead 
electrocardiogram was recorded continuously during exercise testing. Blood pressure was 
registered on a regulatory basis using a manual cuff sphygmomanometer. Patients were 
encouraged to continue the exercise until their peak oxygen uptake (denoted as VO2 max) was 
reached or when they became symptomatic, or discontinuation was indicated for safety 
reasons. Oxygen uptake, carbon dioxide production, and minute ventilation were measured 
using breath-by-breath gas analysis. Peak VO2 was determined as an average value of the two 
highest VO2 values at peak performance, data were expressed as mL/kg/min [16-18]. 
 
Biochemical measurements 
Plasma Galectin-3 levels were determined by an enzyme-linked immunosorbent assay 
(ELISA) developed by BG Medicine (Galectin-3 assayTM, BG Medicine, Inc., Waltham, USA). 
The assay quantitatively measures the concentration of human galectin-3 levels in EDTA 
plasma. This assay has a high sensitivity (lower limit of detection 1.13 ng/mL) and exhibits no 
cross-reactivity with collagens or other members of the galectin family. Calibration of the 
assay was performed according to the manufacturer’s recommendation and values were 
normalized to a standard curve [9, 10]. NT-proBNP levels were measured by an immuno-
electro-chemiluminesence method (Elecsys, Roche Diagnostics, Basel, Switzerland) [21]. The 
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Data are expressed as mean ± standard deviation (SD) when normally distributed. Data 
are expressed as medians with lower and upper quartiles when non-normally distributed. 
Categorial variables are expressed as frequencies and percentages. Baseline 
characteristics were divided into quartiles of plasma galectin-3 levels. Differences between 
groups were compared using the 1-way analysis of variance test, Kruskal-Wallis test or Chi-
square test where appropriate. For further analyses, logarithmic transformation was performed 
to achieve a normal distribution for skewed variables. The Pearson correlation coefficient was 
employed to test correlations between galectin-3 and other variables.   
All tests were two-sided and a p-value <0.05 was considered statistically significant. All 
statistical analyses were performed using STATA version 11.0 (StataCorp LP) and SPSS 




Baseline characteristics of all patients, according to quartiles of plasma galectin-3, are 
described in table 1. Overall, mean age of the study population was 61±11 years, and 80% 
were males. Around 40% patients had NYHA-class III and IV. Mean LVEF was 32±9%. 
Mean eGFR was 80±21 mL/min/1.73m2, mean NT-proBNP value was 388 (154-823) ng/L, 
mean VO2 max was 21.7±6.1 mL/kg/min. All patients were on standard medication for HF, 
including an ACE inhibitor (ACEi) or angiotensin II receptor blocker (ARB), beta-blocker 
(BB), and diuretics. 
 
Galectin-3 and parameters of disease severity and renal function 
Plasma galectin-3 levels displayed a moderately significant correlation with levels of NT-
proBNP (R=0.26; p=0.009; figure 1A), but not with NYHA-class (R=0.13; p=0.230). 
Furthermore, galectin-3 levels also showed a correlation with creatinin levels (R=0.24; 
p=0.014) and with levels of plasma urea (R=0.33; p=0.001). In addition, linear regression 
analysis showed a significant association between plasma galectin-3 levels and eGFR (R=-
0.30; p=0.002; figure 1B). When adjusted for age and gender plasma galectin-3 levels are not 
correlated with eGFR, suggesting that some of the prognostic power of galectin-3 may be 
associated with age and gender.  
 
Correlation between plasma galectin-3 levels and exercise capacity 
At baseline, VO2 max correlated with increasing galectin-3 levels (R=-0.24; p=0.016; 
figure 1C). In contrast, the level of plasma galectin-3 is not associated with the resting oxygen 
uptake (R=-0.11; p=0.285). Furthermore, linear regression analysis showed a correlation 
between the plasma galectin-3 levels and the VO2 max (p=0.016). However, when corrected 
for age and gender, plasma galectin-3 is no longer correlated with VO2 max (figure 1). 
 



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































We analyzed the relation between plasma galectin-3 and different echocardiographic 
parameters. The interactions are described in table 1. The results show that increased plasma 
galectin-3 levels are not associated with parameters of diastolic function (E/A, p=0.872; E/E', 
p=0.351; IVRT, p=0.332; Dct, p=0.662) or systolic function (Simpson LVEF%, p=0.373) 
(table 1). Linear regression analysis showed that there is no correlation between plasma 
galectin-3 and LVEF (R=-0.21; p=0.105; figure 1D). 
 
 
Figure 1 Univariate relation (and 95% confidence intervals) between log galectin-3 in HF patients and renal 
function (A), NT-proBNP (B), VO2 max (C) and LVEF (D) 
 
Discussion 
The present data shows that if galectin-3 levels in patients with chronic HF are high at 
baseline, this is strongly associated with increased creatinin, increased urea and decreased 
eGFR. Furthermore, high galectin-3 levels at baseline are associated with increased levels of 
NT-proBNP. However, when corrected for age and gender, plasma galectin-3 shows no 
significant relation with eGFR. 
A B 
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We observed a strongly correlation between plasma galectin-3 and VO2 max, however, 
this correlation is abrogated after correction for age and gender. Finally, no correlation was 
found between increased levels of galectin-3 and echocardiographic measurements of cardiac 
function in chronic HF.  
Galectin-3 was discovered around ten years ago. It is widely distributed throughout the 
entire body, including heart, lung, liver and kidney [23]. The role of galectin-3 in fibrosis and 
inflammation has been elucidated in recent years. The first experimental evidence showing 
involvement of galectin-3 in chronic HF stems from a landmark study of Sharma and 
colleagues [4]. They demonstrated that galectin-3 could be used as a new target for 
intervention in chronic HF. Since then, clinical trials have consistently shown potential 
clinical usefulness of galectin-3 as a prognostic biomarker for chronic HF. Herein, van 
Kimmenade et al. were the first to evaluate the prognostic and predictive value of galectin-3 
as a biomarker in acute and chronic HF [11]. 
The PRIDE study revealed that plasma galectin-3 was a superior predictor when 
compared to NT-proBNP. High plasma galectin-3 levels are associated with left ventricular 
filling and decreased diastolic function [7]. In contrast, in our study we found no relation 
between plasma galectin-3 levels and echocardiographic parameters for diastolic and systolic 
function in this cohort of patients with chronic HF. We argue that the discrepancy between 
previous reports and our study is due to fact that the patient’s population in the PRIDE study 
is different from our present study (acutely decompensated HF in PRIDE vs. well defined 
stable chronic HF in the present study). 
In the DEAL-HF study, plasma galectin-3 levels were increased in patients with higher 
NT-proBNP levels. Furthermore high galectin-3 levels were associated with decreased eGFR. 
Additionally, in the PRIDE and the PREVEND studies, our group showed a correlation 
between increased plasma galectin-3 levels and cardiovascular risk factors and renal 
dysfunction. Notably, growing evidence shows that renal dysfunction is frequently observed in 
cardiovascular disease [25, 26], being one of the most powerful predictors in chronic HF 
prognosis and plays an important role in the pathophysiologic process of HF [27]. Taken 
together, evidence is accumulating that increased plasma galectin-3 levels are associated with 
cardiovascular disease and renal dysfunction. We confirm these observations in our present 
study. 
Interestingly, in a recently published paper by Gopal et al. plasma galectin-3 is inversely 
related to renal function in patients with and without clinical HF [28]. They showed that 
galectin-3 correlated strongly with eGFR, both in patients with HF and in patients without HF, 
and this relationship was unaffected by the presence or absence of clinical HF. They 
concluded that concentrations of plasma galectin-3 do not seem to depend on the level of 
compensation or type of HF. Furthermore, the relationship between galectin-3 and renal 
function seems to be affected little or not at all by the presence or absence of clinical HF. 
Cardiopulmonary aerobic capacity testing is one of the diagnostic tools for chronic HF. 
Decreased peak exercise capacity is associated with poor prognostic and decreased patient 
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survival. In the HF-ACTION study, plasma galectin-3 levels were measured in 895 subjects 
with chronic HF from a randomized controlled trial of exercise training in patients with 
chronic HF (NYHA class II, III or IV). Galectin-3 was associated with increased NYHA-class, 
and lower VO2 max [13]. The present data confirms that increased plasma galectin-3 levels 
are associated with decreased VO2 max. 
Some limitations apply to this study. This is a sub study of the BENEFICIAL study and 
the BENEFICIAL study was not powered for the current analyses. After correction for age and 
gender, plasma galectin-3 shows no significant relation with eGFR, VO2 max and 
echocardiographic measurements of cardiac function, where previous studies do. This is 
probably due to the low number of subjects participating in this study.  
As a multifunctional biomarker, galectin-3 promotes macrophage migration, 
myofibroblast activation and collagen synthesis, all involved in organ fibrogenesis process. 
The relationship of galectin-3 with other cardiovascular markers (e.g.: LVEF, NT-proBNP), 
renal function and VO2 max suggests a role of galectin-3 in integrating these mechanisms in 
the progression of HF. However, still much is unknown about the role of galectin-3 in 
cardiovascular disease. Well-designed studies are needed to further elucidate its role in 
chronic HF.  
 
Conclusions 
This study demonstrates that high plasma galectin-3 levels are correlated with poor renal 
function and lower aerobic capacity in patients with chronic HF. No significant relation was 
observed between plasma galectin-3 levels and echocardiographic parameters for chronic HF. 
Although much about the details of galectin-3 in HF remains vague, continued efforts at 
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Heart failure (HF) is a syndrome characterized by high mortality, frequent hospitalization, 
poor quality of life and multiple co-morbidities attributable largely to cardiac structural 
changes with associated cardiac dysfunction [1, 2].  Pathological changes of the myocardium 
is the primary cause of cardiac remodeling, which includes structural changes such as myocyte 
loss, apoptosis, hypertrophy and myofilament disorganization, as well as disturbance of 
extracellular matrix homeostasis, collagen synthesis and deposition [3-14].  Such changes 
therefore lead to cardiac dysfunction.  
Recent pharmacological therapy for HF focuses on angiotensin converting enzyme 
inhibitors and beta blockers which provide stability and even reverse adverse cardiac 
remodeling [15-19].  However, HF appears to be not only the result of myocardial injury or 
hemodynamic overload as commonly perceived, it is also the result of an interaction among 
genetics, neurohormonal, inflammatory and biochemical factors – some of the latter being 
referred to as biomarkers. Some biomarkers are not only indicative of an increased risk, but 
also serve as potential targets for therapeutic intervention. One such novel biomarker is 
galectin-3 (Gal-3) [20]. Macrophage derived Gal-3 is associated with activated myofibroblasts 
and increased synthesis and deposition of collagen. The role of Gal-3 in cardiac remodeling 
has been intensively discussed in recent years [21-26], whereas little attention has been given 
to genetically- and pharmacologically-targeted therapy for Gal-3 in cardiac remodeling and 
renal dysfunction. 
In this thesis we have employed several models of cardiac remodeling and chronic heart 
failure to investigate the role of Gal-3 under pathophysiological conditions. Chapter 1 
discusses the characteristics of Gal-3 and its therapeutic implication. In chapter 2 and 3, we 
provided an overview of Gal-3 in cardiac remodeling and heart failure, aiming to systemically 
describe the chemical characteristics of Gal-3 and its biological role including expression 
levels of Gal-3 in physiologically normal and pathologically-altered tissue specimens. 
Furthermore, we also enumerate the potential utility of Gal-3 in experimental models of 
cardiac remodeling and clinical HF patients.  Finally, we discussed the role of Gal-3 in 
modulating the fibrosis pathway and further point out Gal-3 as “culprit biomarker” that 
involved in the pathophysiology circle of cardiac remodeling and HF. In chapter 4 we 
evaluated whether Gal-3 is a relevant therapeutic target in cardiac remodeling and HF. In this 
study we firstly employed Gal-3 knock out (Gal3-KO) and wild-type (WT) mice which were 
subjected to angiotensin II or transverse aortic constriction (TAC) to provoke cardiac 
remodeling. Secondly, the Gal-3 inhibitor, N-acetyllactosamine (Gal3i), was administered to 
hypertensive TGR (mREN2)27 (REN2) rats and WT mice with TAC. The homozygous REN2 
rat model is a well-defined model for progressive cardiac remodeling. We demonstrated that 
the inhibition of Gal-3 by genetic disruption or pharmacological intervention halted the 
progression of cardiac remodeling, attenuated myocardial fibrogenesis and preserved LV 
function. These beneficial effects can be explained, at least in part, by the lower number of 
myofibroblasts in combination with diminished collagen synthesis, processing and cross-
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linking. Finally, to elucidate the beneficial effects of Gal-3 inhibition on myocardial 
fibrogenesis, cultured fibroblasts were treated with Gal-3 in the absence or presence of Gal3i. 
We found that inhibition of Gal-3 was associated with a down-regulation of collagen 
production (collagen I and III), collagen processing, cleavage, cross-linking and deposition. 
Collectively, we confirm that genetic disruption and pharmacological inhibition of Gal-3 
attenuates cardiac fibrosis, LV dysfunction and subsequent HF development, suggesting that 
the drugs binding to Gal-3 may be potential therapeutic candidates for the prevention or 
reversal of HF with extensive fibrosis.  
Renal dysfunction is frequently observed in cardiovascular disease [27, 28], and is one of 
the strongest predictors in heart failure prognosis, playing an important role in the 
pathophysiological process [29]. We therefore performed a subsequent study in the well-
established REN2 rat model with hypertensive end-organ damage (chapter 5), and showed 
that targeted inhibition of Gal-3 attenuates progressive hypertensive nephropathy. Over a 6-
week time course, the untreated REN2 rats developed substantial proteinuria, a typical marker 
of glomerulosclerosis. We observed that treatment with Gal3i completely prevented the 
development of proteinuria and the associated histological markers of kidney damage. 
Interestingly, this pathological conversion was apparently without effects on blood pressure in 
REN2 rats treated with the Gal3i. We concluded that Gal-3 exerts its protective effects 
probably by directly acting on the renal glomeruli, parenchyma and tubuli. This new finding 
offers a novel insight to new therapies for HF associated with chronic kidney disease (CKD). 
Taken together, we reveal that drugs binding to Gal-3 may be potential therapeutic candidates 
in cardiac remodeling or the related renal dysfunction.  
To further investigate the important role of Gal-3 in chronic heart failure (CHF), we 
examined the correlation of plasma Gal-3 levels with cardiopulmonary aerobic capacity and 
cardiac function in patients with CHF (chapter 6). In this clinical cohort, we measured 
plasma levels of Gal-3 in 99 patients with stable CHF with NYHA class II-IV. All patients 
had left ventricular ejection fraction (LVEF) ≤0.45 and ability capacity to undergo 
cardiopulmonary exercise testing. Analysis of the results showed that high Gal-3 levels were 
associated with poor renal functional: creatinine (Creat), blood urea nitrogen (BUN), 
estimated glomerular filtration rate (eGFR), high levels of N-terminal pro-brain natriuretic 
peptide (NT-proBNP) and lower peak VO2. Additionally, linear regression analysis predicted 
significant correlations between the plasma Gal-3 level and aerobic capacity (VO2 max) and 
renal function (eGFR). However, Gal-3 did not further predict the peak oxygen uptake (VO2 
max) and renal function after adjustment for age and gender. Moreover, no significant 
relations were observed between the plasma Gal-3 and diastolic function (E/A, and E/E') or 
systolic function (Simpson LVEF%). Finally, we demonstrated that high plasma Gal-3 levels 
were associated with poor renal function and lower aerobic capacity in patients with CHF. 
From all these experimental and clinical studies, we draw the conclusion that macrophage-
derived Gal-3 is associated with myofibroblast-induced collagen synthesis and deposition, a 




Gal-3 as a multifunctional biomarker participates in fibrogenesis and inflammatory 
responses [21-26][30].  In our present studies, we further confirmed that the increased 
expression of Gal-3 enhanced myofibroblast activation with subsequent increases in collagen 
synthesis and deposition in cardiac remodeling and progressive heart failure, which were in 
turn attenuated by gal3i treatment. However, progressive cardiac remodeling is a complex 
process which is not only the result of the generation of adverse fibrosis, but also because of 
chronic inflammatory responses. Therefore, during the cardiac remodeling process, the 
interaction between fibrosis and inflammation cannot be ignored. In the early stage of the 
inflammatory response, resident macrophages induce neutrophil activation and peripheral 
monocytes or macrophages are attracted to the injury area which then activates the release of 
macrophage-derived Gal-3 into the extracelluar matrix compartment. The released Gal-3 then 
takes part in the inflammatory response or fibrogenesis process [31-36].  In our in vitro 
experiment on human dermal fibroblasts, the mechanistic effect of Gal-3 in fibrogenesis has 
been clearly defined herein, however, the underlining mechanism of Gal-3 in the 
inflammatory response in cardiac remodeling should be addressed in future studies.  
Additionally, myocyte hypertrophy, apoptosis or necrosis is one of the main causes 
leading to cardiac remodeling. As myocytes are stretched and become hypertrophied, there is 
an increase in the local production or release of angiotensin II and endothelin.  Subsequently, 
increased angiotensin II and cytokines stimulate collagen synthesis, leading to fibrosis and 
remodeling of the extracellular matrix [37-40].  From our group, analysis of gene array data of 
neonatal cardiomyocyte hypertrophy shows that Gal-3 expression is up-regulated 
approximately 2-fold [41]. The above evidence proves that Gal-3 is most likely also involved 
in cardiomyocyte hypertrophy in the cardiac remodeling process.  Nevertheless, the regulating 
pathway and mechanism linking hypertrophic cardiomyocytes and Gal-3 is still unclear, 
providing a challenge for future study. 
Thirdly, previous experimental and clinical studies demonstrated that (ACEi) alleviated 
cardiovascular disease under different pathological conditions such as hypertension, acute 
myocardial infarction, chronic systolic heart failure, stroke and diabetic renal disease. 
However, ACEi is also accompanied with more side-effects, in particular hypotension, 
hyperkalaemia and renal impairment [30, 42-49]. In our present study, chapter 4 and 5 shows 
that pharmacological inhibition of Gal-3 not only attenuated cardiac fibrosis, LV dysfunction 
and subsequent HF development, but also attenuated progressed hypertensive nephropathy in 
an established REN2 rat model. We observed that the treatment with Gal-3 inhibitor 
prevented the development of cardiac remodeling, proteinuria and the associated fibrosis 
markers. Interestingly, this pathological conversion occurred without apparent effects on 
blood pressure in the REN2 rat treated with the Gal3i. Therefore, we conclude that ACEi and 
Gal3i combination should be considered as a viable therapeutic strategy in severe chronic 
heart failure that is accompanied with impaired renal function. 
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Interestingly, it has been recognized that Gal-3 plays a key role in many pathological 
processes via carbohydrate-dependent (and some independent) mechanisms [50-52] that are 
amenable to therapy.  The intriguing findings related to galectin-3 biology encourage 
researchers to utilize a number of ways to block or inhibit galectin-3 and its signal 
transduction. The ongoing research includes galectin-3 knock-out mice (mice deficient for the 
gene that encodes galectin-3), the use of small interfering RNA (siRNA) that silence galectin-
3 gene activity, and the use of certain complex carbohydrate molecules, e.g. pectins. The 
studies with carbohydrate molecules takes advantage of the fact that galectin-3 has a built-in 
carbohydrate “switch” that can activate and de-activate galectin-3’s activity. These 
carbohydrates, such as lactose (Lac), N-acetyllactosamine (N-lac) and modified citrus pectins 
(MCP) are complex oligosaccharides that are present in a variety of foods. The present thesis 
has investigated the therapeutic efficiency of N-lac in pathophysiological cardiac remodeling 
and heart failure.  However, when considering economic and health benefits, the advantage of 
pectins is that it is easily and commercially available for anti-galectin-3 therapy. Pectins are 
the complex large carbohydrate molecules and a natural source of galectin-3 inhibition.  Their 
structure consists of an important part of cell walls and material that can be found in between 
plant cells, providing structure to fruits and vegetables. Furthermore, recent research found 
that the effect of MCP on kidney fibrosis [53]. Moreover, our unpublished data involving a 
galectin-3 chemotaxis assay also shows that recombinant galectin-3 significantly induces 
monocyte migration, which could be markedly attenuated after treatment with MCP.  
Therefore, we consider pectins are viable low-cost and natural source of galectin-3 inhibition, 
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Hartfalen (HF) is een syndroom dat gekenmerkt wordt door een hoge mortaliteit, 
frequente hospitalisaties, een slechte kwaliteit van leven en veel comorbiditeit. Hartfalen 
wordt grotendeels veroorzaakt door structurele veranderingen van de hartspier en de hiermee 
geassocieerde afname van de pompfunctie van het hart [1,2]. Primaire oorzaken van 
remodellering van de hartspier (Engels: cardiac remodeling) zijn pathologische veranderingen, 
zoals het verlies van hartspiercellen (cardiomyocyten), apoptose, hypertrofie, disorganisatie 
van myofilamenten en een verstoring in het evenwicht van de extracellulaire matrix. 
Uiteindelijk leidt dit tot een toename van collageen aanmaak en afzetting [3-14] en 
gezamenlijk leiden deze veranderingen tot een verminderde functie van de hartspier. 
Farmacologische therapie voor hartfalen bestaat voornamelijk uit  ACE-remmers en beta-
blokkers, die zorgen voor stabilisatie van het ziekteproces en zijn zelfs in staat de reeds 
ontstane cardiale remodellering weer teniet te doen [15-19] . Maar hartfalen is niet alleen het 
resultaat van schade aan de hartspier of overbelasting van het hart- en vaatstelsel zoals vaak 
wordt aangenomen. Het is ook het resultaat van de interactie tussen genetische, 
neurohormonale, inflammatoire en biochemische factoren – waarvan enkele ook biomarkers 
genoemd worden. Sommige biomarkers duiden  alleen op een verhoogd risico, maar enkelen 
kunnen ook gebruikt worden als therapeutisch aangrijpingspunt. Een dergelijke biomarker is 
galectine-3 (Gal-3) [20]. Gal-3, dat uitgescheiden wordt door macrofagen, is geassocieerd met 
geactiveerde myofibroblasten en toegenomen aanmaak en afzetting van collageen. De rol van 
Gal-3 in cardiale remodellering is de afgelopen jaren zeer uitvoerig beschreven [21-26], maar 
hierbij is weinig aandacht uitgegaan naar Gal-3 als farmacologisch of genetisch doelwit voor 
therapie bij cardiale remodellering en verslechterde nierfunctie.  
In dit proefschrift hebben we diverse modellen van cardiale remodellering en chronisch 
hartfalen gebruikt om de rol van Gal-3 in pathofysiologische condities te onderzoeken. In 
hoofdstuk 1 worden de eigenschappen van Gal-3 en de therapeutische mogelijkheden 
besproken. In hoofdstuk 2 en 3 wordt een overzicht gegeven van Gal-3 in cardiale 
remodellering en hartfalen. Hierin worden op systematische wijze de chemische en 
biologische eigenschappen van Gal-3 beschreven, waaronder de expressie van Gal-3 in 
gezond en ziek weefsel. Daarnaast wordt ook een opsomming gegeven van de mogelijke 
toepasbaarheid van Gal-3 in experimentele diermodellen van cardiale remodellering en in 
patiënten met hartfalen. Ten slotte wordt de rol van Gal-3 besproken als modulerende factor 
bij het ontstaan van fibrose en wordt benadrukt dat Gal-3 een belangrijke biomarker is, die 
betrokken is bij de pathofysiologische cyclus van cardiale remodellering en hartfalen. In 
hoofdstuk 4 wordt beschreven dat Gal-3 een relevant therapeutisch doelwit is voor cardiale 
remodellering en hartfalen. In deze eerste studie is gebruik gemaakt van Gal-3 knock-out 
(Gal3-KO) en wild-type (WT) muizen waarbij transversale aorta constrictie (TAC) of 
angiotensine II-infusie werd toegepast om cardiale remodellering te bewerkstelligen. 
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Vervolgens werd een Gal-3-remmer, N-acetyllactosamine (Gal3i), toegediend aan 
hypertensieve TGR (mREN2)27 (REN2) ratten en WT muizen met TAC. Het homozygote 
REN2 rat model is een goed omschreven model voor progressieve cardiale remodellering. We 
hebben in deze studie aangetoond dat remming van Gal-3 door genetische of farmacologische 
interventie de progressie van cardiale remodellering stopt, de vorming van  fibrose voorkomt 
en zorgt voor behoud van LV functie. Deze gunstige effecten kunnen gedeeltelijk verklaard 
worden door een lager aantal myofibroblasten in combinatie met de verminderde aanmaak, 
afzetting en cross-linking van collageen. Om de gunstige effecten van de remming van Gal-3 
op myocardiale fibrogenese te aan te tonen, werden fibroblasten in vitro behandeld met Gal-3 
in combinatie met de Gal3i. Hieruit bleek dat remming van Gal-3 geassocieerd is met een 
down-regulatie van collageen productie (collageen I en III) evenals collageen verwerking, 
splitsing, cross-linking en afzetting. Deze resultaten samen bevestigen dat genetische en 
farmacologische inhibitie van Gal-3 zorgt voor vermindering van cardiale fibrose, LV 
dysfunctie en de hieruit volgende ontwikkeling van HF. Deze resultaten suggereren dat een 
Gal-3 remmer een potentiële kandidaat voor therapie zou kunnen zijn voor de preventie of 
verbetering van HF met uitgebreide fibrose.  
Nierfunctiestoornissen worden frequent geobserveerd in cardiovasculaire ziekte [27,28]. 
Nierfunctiestoornissen zijn een van de sterkste voorspellers voor de prognose van hartfalen en 
spelen een belangrijke rol in het pathofysiologische proces [29]. Daarom hebben we een 
studie uitgevoerd in het REN2 rat model, waarbij orgaan schade geïnduceerd werd als gevolg 
van hypertensie. In dit model hebben we aangetoond dat de remming van Gal-3 zorgt voor een 
vermindering van progressieve, hypertensieve nierziekte (hoofdstuk 5). Gedurende een 
periode van 6 weken ontwikkelden onbehandelde REN2 ratten substantiële proteïnurie, een 
typische marker van glomerulosclerosis. Hierbij zagen we dat de behandeling met Gal3i 
zorgde voor preventie van proteïnurie en een verlaging gaf van de, met nierschade 
geassocieerde, markers. Daarnaast was het opvallend dat de behandeling met Gal3i geen 
effect had op de bloeddruk van de REN2 ratten. Hieruit kunnen we concluderen dat Gal-3 zijn 
beschermende effect uitoefent door een directe werking op de renale glomeruli, het 
parenchym en de tubuli. Deze resultaten bieden nieuw inzicht in nieuwe therapieën voor 
hartfalen geassocieerd met chronische nierziekte. Uit de, in dit hoofdstuk beschreven, studie 
kunnen we concluderen dat Gal-3 remmers, een potentieel therapeutische kandidaat kunnen 
zijn bij cardiale remodellering of hieraan gerelateerde verminderde nierfunctie.  
Om het effect van Gal-3 in chronisch hartfalen (CHF) verder te onderzoeken, hebben we 
onderzocht wat de correlatie is tussen Gal-3 niveau in het plasma en cardiopulmonale aerobe 
capaciteit en cardiale functie in patiënten met CHF (hoofdstuk 6). In dit klinische cohort, 
hebben we de Gal-3 levels in het plasma  gemeten in 99 patiënten met stabiel CHF met 
NYHA klasse II-IV. Alle patiënten hadden een linker ventrikel ejectiefractie (LVEF) < 0.45 
en waren in staat een cardiopulmonale inspanningstest te ondergaan. De analyse van deze 
resultaten toonde dat een hoog Gal-3 niveau  geassocieerd was met een slechte nierfunctie: 
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creatinine, bloed ureum stikstof en geschatte glomerulaire filtratie snelheid (eGFR), maar ook 
met hoge niveau’s van N-terminal pro-brain natriuretisch peptide (NT-proBNP) en een lage 
piek VO2. Bovendien voorspelde lineaire regressie analyse significante correlaties tussen Gal-
3 levels in het plasma  en aerobe capaciteit (VO2 max) en nierfunctie (eGFR). Echter werden 
deze correlaties niet meer gevonden na correctie voor leeftijd en geslacht. Er werden geen 
significante relaties gevonden tussen plasma Gal-3 levels en de diastolische functie (E/A, en 
E/E’) of de systolische functie (Simpson LVEF%). In deze studie hebben we aangetoond dat 
een hoog plasma Gal-3 level geassocieerd is met een slechte nierfunctie en een lage aerobe 
capaciteit in patienten met CHF. Uit deze experimentele en klinische studies kunnen we de 
conclusie trekken dat Gal-3 geassocieerd is met synthese en afzetting van collageen die door 
myofibroblasten geïnduceerd is - een proces dat betrokken is in pathofysiologische cardiale 
remodellering en hartfalen.  
 
Toekomstperspectieven 
Gal-3 is een multifunctionele biomarker en speelt een rol bij de fibrose en 
ontstekingsreacties [21-26][30]. In de studies die in dit proefschrift beschreven worden, 
hebben we bevestigd dat een verhoogde expressie van Gal-3 in cardiale remodellering en 
progressief hartfalen, zorgt voor meer myofibroblast activatie met bijbehorende toename van 
synthese en afzetting van collageen en wat verminderd werd door de behandeling met Gal3i. 
Cardiale remodellering is echter een progressief en complex proces dat niet alleen veroorzaakt 
wordt door fibrose, maar ook door een chronische ontstekingsreactie. Daarom kan de 
interactie tussen fibrose en onsteking, tijdens het proces van cardiale remodellering, niet 
genegeerd worden. In de vroege fase van de ontstekingsreactie, zorgen macrofagen voor de 
activatie van neutrofielen, monocyten of macrofagen die naar de onsteking worden 
toegetrokken en deze cellen zorgen daar voor de afgifte van Gal-3 in de extracellulaire matrix. 
Gal-3 maakt deel uit van de ontstekingsreactie maar ook van het proces van fibrose vorming 
[31-36]. In ons in vitro experiment met humane dermale fibroblasten, worden de mechanische 
effecten van Gal-3 op de vorming van fibrose duidelijk gedefinieerd. Het onderliggende 
mechanisme van Gal-3 op de ontstekingsreactie in cardiale remodellering moet echter nog 
verder onderzocht worden in toekomstige studies.  
Bovendien zijn hypertrofie, apoptose en necrose van cardiomyocyten belangrijke 
oorzaken voor het ontstaan van cardiale remodellering. Wanneer myocyten groter worden en 
hypertrofie ontstaat, komt hierdoor angiotensine II en endotheline vrij. Een verhoging van de 
levels van  angiotensine II en cytokines zorgt vervolgens voor  de synthese van collageen, wat 
leidt tot fibrose en remodellering van de extracellulaire matrix [37-40]. Analyse van gene 
array data van hypertrofe, neonatale cardiomyocyten, dat in onze onderzoeksgroep werd 
uitgevoerd, liet zien dat de Gal-3 expressie verdubbelde. Bovenstaand resultaat suggereert dat 
Gal-3 ook betrokken is bij de hypertrofie van cardiomyocyten in het proces van cardiale 
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remodellering. Niettemin blijft het mechanisme achter de relatie tussen hypertrofe 
cardiomyocyten en Gal-3 onduidelijk, waardoor dit een uitdaging blijft voor toekomstig 
onderzoek.  
Ten derde hebben experimentele en klinische studies uitgewezen dat ACE-remmers 
zorgen voor een verbetering van cardiovasculaire ziekten onder verschillende pathologische 
condities zoals hypertensie, acuut myocardinfarct, chronisch systolisch hartfalen, beroerte en 
diabetische nierziekte. Het gebruik van ACE-remmers gaat echter ook gepaard met 
bijwerkingen, in het bijzonder hypotensie, hyperkaliëmie en een verslechtering van de 
nierfunctie [30, 42-49]. In onze studies die beschreven worden in de hoofdstukken 4 en 5, 
tonen we aan dat farmacologische remming van Gal-3 niet alleen zorgt voor verminderde 
cardiale fibrose, verslechterde functie van het linkerventrikel en daaropvolgende ontwikkeling 
van hartfalen. Ook zorgt remming van Gal-3 voor het tegengaan van de progressie van 
hypertensieve nierziekte zoals in een REN2 rat model werd vastgesteld. We hebben 
vastgesteld dat de behandeling met Gal3i zorgt voor preventie van ontwikkeling van cardiale 
remodellering, proteïnurie en geassocieerde markers van fibrose. Interessant genoeg gaat deze 
pathologische conversie gepaard zonder effecten op de bloeddruk in de REN2 rat die 
behandeld werd met Gal3i. Daarom concluderen we dat een combinatie van ACE-remming en 
Gal3-remming snel moet worden overwogen als therapeutische strategie in ernstig chronisch 
hartfalen dat gepaard gaat met een verslechterde nierfunctie.  
Het is bekend dat Gal-3 een belangrijke rol speelt in vele pathologische processen via 
koolhydraat-afhankelijke (en sommige onafhankelijke) mechanismen [50-52] die gevoelig 
zijn voor therapie. Deze intrigerende bevindingen gerelateerd aan Gal-3 biologie moedigen 
onderzoekers aan om een aantal methoden te gebruiken om Gal-3 en haar signaal transductie 
te blokkeren of te remmen. Lopend onderzoek behelst onder andere Gal-3 KO muizen 
(muizen die deficiënt zijn voor het gen dat codeert voor Gal-3), het gebruik van short 
interfering RNA (siRNA) die de Gal-3 expressie verminderen, en het gebruik van complexe 
koolhydraat moleculen, bijvoorbeeld pectines. De studies met koolhydraat moleculen maken 
gebruik van het feit dat Gal-3 een ingebouwde “koolhydraat-switch” heeft die Gal-3 activiteit 
kan activeren en de-activeren. Deze koolhydraten, zoals lactose (Lac), N-acetyllactosamine 
(N-Lac; Gal3i) en gemodificeerde citrus pectines (MCP) zijn complexe oligosacchariden die 
aanwezig zijn in verschillende soorten voedsel. In dit huidige proefschrift werd de 
therapeutische effectiviteit van N-Lac onderzocht in pathofysiologische cardiale remodellering 
en hartfalen. Wanneer echter economische en gezondheidsrisico’s overwogen worden is het 
voordeel van pectines dat zij gemakkelijk en commercieel beschikbaar zijn voor anti-Gal3 
therapie. Pectines zijn complexe, grote koolhydraat moleculen en zijn een natuurlijke bron 
voor Gal-3 remming. De structuur van pectines bestaat voor een belangrijk deel uit celwanden 
en materiaal dat gevonden kan worden in cellen van planten, en zorgt op die manier voor 
structuur in fruit en groente. Ook heeft recent onderzoek uitgewezen dat MCP zorgt voor 
preventie van renale fibrose [53]. Daarnaast heeft nog ongepubliceerde data betreffende een 
Nederlandse Samenvatting 
144 
Gal-3 chemotaxis assay uitgewezen dat recombinant Gal-3 zorgt voor significante inductie 
van migratie van monocyten, die op haar beurt weer geremd kan worden door behandeling 
met MCP. Daarom moeten pectines beschouwd worden als een levensvatbare, goedkope en 
natuurlijk bron voor Gal-3 remming en zou dit in de toekomst getest moeten worden in 
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